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Multiple nivåer av genregulering: cellesylus, epigenetikk og mikroRNA
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Ago Argonaute 
APC Anaphase promoting complex 
ATM Ataxia telangiectasia mutated  
ATR Ataxia telangiectasia and Rad3-related protein 
BER Base excision repair  
BIR Break-induced replication 
CDK Cyclin-dependent kinase 
CKI Cyclin-dependent kinase inhibitor 
CLL Chronic lymphocytic leukemia  
CPD Cyclobutane Pyrimidine Dimer 
CPG Cancer predisposition gene 
DDR DNA damage response  
dHJ Double Holliday junction 
DSB  Double strand break 
ES cells Embryonic stem  cells  
FA Fanconi Anemia  
Fox protein Forkhead box protein 
G1 phase Growth phase 1 or Gap phase 1 
G2 phase Growth phase 2 or Gap phase 2 
GGR Global genomic repair  
H3 Histone 3 
H3K27me3 Histone 3 lysine 27 tri-methylation 
H3K4me3 Histone 3 lysine 4 tri-methylation 
Hox genes  Homeotic genes 
HR Homologous recombination  
KAP-1 KRAB-associated protein-1 
lincRNAs  Long intergenic non-coding RNAs 
lncRNAs Long non-coding RNAs 
MEF Mouse embryonic fibroblast 
miRNA MicroRNA 
MMEJ Microhomology-mediated end joining  
MMR Mismatch repair  
MMS Methyl methanesulfonate  
M phase Mitosis or mitotic phase 
mRNA Messenger RNA 
NER Nucleotide excision repair  
NHEJ Non-homologous end joining  
nt Nucleotide 
PAZ Piwi Argonaute-zwille 
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PcG Polycomb group  
PCNA Proliferating cell nuclear antigen 
PCR Transcriptional-repressive complexes  
pri-miRNA Primary miRNA 
qRT-PCR  Quantitative real-time PCR 
Rb Retinoblastoma 
RISC RNA-induced silencing complex 
S.cerevisiae  Saccharomyces cerevisiae (yeast) 
SDSA Synthesis-dependent strand annealing 
SILAC Stable isotope labeling by amino acids in cell culture  
siRNA Small interfering RNA 
S phase  DNA synthesis phase or DNA synthetic phase 
ssDNA Single-stranded DNA  
ssRNA Single stranded RNA 
SWI/SNF SWItch/Sucrose NonFermentable 
TCR Transcription coupled repair  
UTR Untranslated region  
XP Xeroderma pigmentosum  
YY1 Yin Yang 1 
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Eukaryotes have evolved a complex system of gene regulation compared to prokaryotes. In 
eukaryotes, protein expression is regulated at multiple levels in the cells, including regulation 
by modifications of histones and DNA, regulation of mRNA levels and post transcriptional 
modifications. This complexity is believed to be important in the generation and maintenance 
of the different cell types found in multicellular organisms (reviewed in (1)).  
In prokaryotes, there is a strong correlation between genome size and gene number (2). In 
Eukaryotes, however, a large proportion of nuclear DNA is non-coding. The non-coding parts 
of the genome have been subject to increased interest in the last two decades and many 
important discoveries have been made with regards to the role of non-coding RNAs in gene 
regulation. One type of non-coding RNA that is shown to play an essential role in gene 
regulation is a class of ~22 nucleotide long small RNAs called microRNAs (miRNAs). The 
first miRNA was discovered by Victor Ambros’ lab in 1993 in the nematode C. elegans (3). 
At that time little was known about the importance of these small RNAs apart from their role 
in regulating the timing of development in the worm. In 2001, a much larger set of small 
RNAs was discovered by three individual laboratories (4-6), and the term miRNAs was 
established. In the years to follow, many laboratories started working on these small RNAs 
which have later been implicated in many biological processes and diseases. Today, small 
RNAs are used both as a tool for silencing genes and as potential biomarkers for diseases, and 
they are often included in studies of gene expression. Even though small RNA biology has 
been intensively studied for more than ten years, several central questions remain to be 
answered. In the current thesis we investigated the role of the miRNA binding protein 
Argonaute 2 (Ago2) by sequencing small RNAs and mRNA in Ago2 knock-out cells. We 
showed that Ago2 knock-out strongly affects Hox gene-expression as well as late growth 
responses in serum starved MEF cells. Moreover, by analyzing miRNAs from the same Ago2 
knock-out cells, we characterized sequence and structure features in miRNAs differential 
expressed between knock-out and wild-type, indicating novel sorting characteristics for Ago2. 
We also included a meta-analysis of published data from deep-sequenced small RNAs 
extracted from protein immunoprecipitation (IP) of the different Ago proteins. This analysis 
confirmed the sorting features found in the Ago2 knock-out cells. 
The field of chromatin remodeling has gained more interest in recent years although the first 
ATP-dependent chromatin remodeling complex, the yeast SWI/SNF, was discovered already 
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in in 1992 (7). The increased interest is partly due to advances in technology resulting in high 
resolution structure of the nucleosome as well as new sequencing methods. Several research 
groups have started to work on how remodeling enzymes corporate with DNA repair proteins 
to facilitate repair of damaged DNA. Adding to this complexity comes the discovery that 
small RNAs may have a role in mediating DNA damage response; however, the exact 
mechanism for this interaction is not known (8,9). In the current thesis we try to integrate 
DNA repair genes and chromatin remodeling genes, focusing on their role in the cell cycle. 
We analyzed cell cycle expression profiles from multiple cell lines and found that several 
DNA repair pathways and chromatin remodeling genes are enriched in specific cell cycle 
phases, indicating that the cell prefers certain repair pathways in specific cell cycle phases. 
Moreover, we provide an extensive update on DNA repair and chromatin remodeling genes. 
We also found that a subset of Polycomb-target genes display replication dependent 
transcription. This may be a mechanism for expressing Polycomb-associated RNAs, which 
perhaps contribute in maintaining the repressive state of these genes during cell division. 
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4.1. Mechanisms and pathways of DNA repair 
The maintenance of genome integrity is crucial for cell survival and to prevent mutations to 
be inherited. Cells have evolved several mechanisms to counteract the effects from agents that 
could inflict damage to the DNA. The DNA damage response (DDR) comprises a series of 
pathways that are distinct in terms of which lesion they process, but still share many of the 
same proteins (10). DNA repair pathway choice is dependent on damage type, but also to a 
large degree on cell cycle phase (11-13) and protein modifications (14,15). The following 
sections describe the major repair pathways, which proteins are involved and the type of 
lesion they target.  
4.1.1. The base excision repair pathway 
Base excision repair (BER) is a repair pathway that corrects small base lesions caused by 
oxidation, deamination and alkylation. The pathway is initiated by one of the many 
mammalian DNA glycosylases that recognize and remove the damaged base (reviewed in 
(16)). The pathway is further completed by a short patch or long patch repair route that uses a 
distinct set proteins to fill and ligate the gap generated by the DNA glycosylase. Short patch 
BER does not depend on replication and is equally efficient in proliferating and 
nonproliferating cells. The major proteins needed for short patch BER after the initiate repair 
by a DNA glycosylase are AP-endonuclease APE1, DNA polymerase β (polβ), DNA ligase 1 
or 3 (LIG1/3), Polymerase 1 (PARP) and XRCC1. Long patch BER on the other hand 
depends on replication proteins and is mainly acting in proliferating cells. After the damaged 
strand is cleaved by APE1, long patch BER uses DNA polymerase δ and ε, PCNA, FEN1 and 
LIG1 to incorporate new nucleotides and repair the damage. The BER pathway is known to 
be up-regulated during S phase (17). 
4.1.2. The nucleotide excision repair pathway 
Nucleotide excision repair (NER) is the principal repair mechanism for helical disorders, 
replication-blocking DNA adducts such as those induced by UV light, and other chemicals 
toxic to the genome (17). In humans, defects in the NER-genes leads to increased sensitivity 
to UV radiation and the clinical disorder Xeroderma pigmentosum (XP) and increased risk of 
skin cancer (18). NER has two modes of repair: global genome repair (GGR) and 
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transcription coupled repair (TCR). The Xeroderma pigmentosum group A protein (XPA) is 
indispensable in both pathways and acts as an important regulator in verifying the damage and 
recruiting other factors to the damage site (19,20). TCR is a specialized pathway that removes 
lesions on the transcribed strand of DNA that block RNA polymerase  (21). GGR and TCR 
differ mostly in the initial steps of repair. XPC-RAD23B recognizes structural changes in the 
DNA and initiates GGR by binding the strand opposite of the lesion. TCR is initiated by 
stalled RNA polymerase on the transcribed strand (22,23). Stalled polymerase represents a 
signal that recruits the two proteins CSA and CSB, which facilitate removal of the damage 
and restart of transcription (24,25). After the initial damage recognition by either GGR or 
TCR the transcription factor II H (TFIIH) complex is recruited. TFIIH is required for the 
unwinding of the DNA around the lesion facilitating the recruitment of XPA and replication 
protein A (RPA) and proteins from the 10/11-subunit complex. RPA activates XPG and 
ERCC1, which cleave the damaged DNA fragment. DNA polymerases δ, ε, and κ fill the 
single strand gap, a process which is coordinated by PCNA (26). DNA Ligase3-XRCC1 and 
DNA Ligase I finally seal the DNA (26). In non-dividing cells this is performed by XRCC1–
LIG3α  (27). The NER pathway is known to be important in G1 phase, but it also function at a 
global level irrespective of cell cycle phase (17,28). 
4.1.3. The mismatch repair pathway 
Mismatch repair (MMR) is a repair pathway specific for base-base mismatches and 
insertions/deletions loops generated during DNA replication and recombination. Some studies 
have reported constant levels of MMR-genes throughout the cell cycle  (29), whereas other 
have reported that the pathway mainly functions during S phase (30). Some of the genes that 
are associated with MMR are: RFC, RPA, ExoI, MSH2, MSH3, MSH6, MutSα/β and MutLα. 
MutSα recognizes short base-base mismatches of 1-2 nucleotides, while MutSβ recognizes 
larger mismatches. It has been suggested that PCNA is helping MutSα and MutSβ to 
recognize mispairs in newly replicated DNA, in addition to its role in DNA synthesis (31-33). 
RFC is required for 3’ directed mismatch excision during repair and facilitates loading of 
PCNA (33). RPA is a DNA-binding protein that seems to be involved in all stages of MMR 
(34). ExoI is an exonuclease that interacts with MSH2 and MLH1 to perform 5’→3’ directed 
repair (35,36).  
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4.1.4. The fanconi Anemia pathway 
Fanconi Anemia (FA) is a genetic disorder caused by mutations in genes responsible in the 
repair of interstrand crosslinks. The Fanconi anemia pathway involves more than 15 genes 
and its main function is to repair interstrand crosslinks (37). The fanconi proteins coordinate 
multiple repair processes such as translesion synthesis, nuclease activity, homologous 
recombination, non-homologous end joining and mismatch repair. Crosslinks in DNA can 
occur both during transcription and replication and repair is therefore needed in all stages of 
the cell cycle. When no homologous template is present the damage can be repaired using 
nucleotide excision repair (38). If a template is present homologous recombination is used to 
remove the crosslink (39). The fanconi pathway is activated through phosphorylation of ATR 
which together with its partner ATRIP (ATR interacting protein) coordinate the downstream 
activation of the fanconi core complex (40). The core complex activates the FANCI/FANCD2 
(I-D2) complex which in turn recruits FAN1 (41). FANCD2 is found to be phosphorylated by 
ATM, an essential step in establishing the intra-S checkpoint (40). Together with the I-D2 
complex, FAN1 localizes at sites of DNA damage. The I-D2 complex also activates BRCA2 
and FANCN which loads the homologous recombination protein RAD51 onto the DNA  (37). 
4.1.5. DNA double-strand repair 
DNA double-strand break (DSB) is a severe type of lesion that can lead to oncogenic 
translocations. Three mechanisms exist to repair DSBs: non-homologous end joining 
(NHEJ) (42); microhomology-mediated end joining (MMEJ) (43); and homologous 
recombination (HR)  (44). The MRN complex consisting of Mre11, Rad50 and Nbs1 plays an 
important role in the initial processing of DSBs prior to repair by the more specific pathways. 
The MRN complex activates the checkpoint kinase ATM in response to DSBs. The decision 
on which pathway to choose depends on which cell cycle phase the damage occur and on 
which factors that are able to access the free DNA ends  (45). The process of creating 3′ 
single-stranded DNA (ssDNA) tails, called resection, is a critical determinant for repair 
pathway choice (45,46). Once resection is initiated, the NHEJ-proteins XRCC5 and XRCC6 
will not bind and the cell is committed to HR. NHEJ is shown to be active throughout the cell 
cycle but the activity increases from late G1 to G2/M phase (47). DSBs that occur during 
chromosome segregation in M phase are likely to be repaired by NHEJ (48). Because 
homologous recombination prefers sister chromatids as template for repair it is suggested that 
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HR is restricted to the S and G2 phases of the cell cycle when sister chromatids are present 
(44,49,50). During G2/M phase the chromatin is highly condensed which makes homology 
search by HR difficult. However, HR can function during G2 if the sister chromatids are in 
proximity to one another. Homologous recombination is divided into three stages: 
presynapsis, synapsis and postsynapsis. In brief, during presynapsis the DNA is prepared for 
repair by forming a region of single-stranded DNA (ssDNA) which is bound by the ssDNA-
binding protein RPA (replication protein A). During synapsis, Rad51 performs homology 
search on the RPA-covered ssDNA (44). Finally, in postsynapsis the HR pathway is separated 
into three sub-pathways (BIR, SDSA and dHj) with separate acting proteins. BRCA2, BLM, 
GEN1 and EME1 are important proteins in this final step of the HR pathway (51,52). 
4.1.6. Direct DNA damage reversal 
In addition to the abovementioned repair systems, the cell can repair lesions without the 
incision of the DNA sugar-phosphate backbone or removal of the damaged base. This 
mechanism is called direct damage reversal and is essentially error-free, however, it has a 
narrower substrate range than other repair pathways (53,54). Three types of direct DNA repair 
have been described: i) removal of UV light-induced photo lesions by photolyases; ii) 
removal of O6- methyl guanine (6-meG) by O6- alkylguanin-DNA alkyltransferases (AGTs); 
iii) removal of N-alkylated base adducts by AlkB family dioxygenases.
UV lesion are generally of two types: cyclobutane pyrimidine dimers (CPDs) and pyrimidine 
pyrimidones (6-4) photoproducts (6-4 PPs) (53). The photolyase enzymes are specifically 
targeting either of the two lesions and they use light to catalyze the repair process (53,55,56). 
Alkylation damage could occur as a result of exposure to a variety of environmental 
compounds including methyl-N’-nitro-N-nitroso-guanidine (MNNG), N-methyl-N-nitrosurea 
(MNU) and methyl methane-sulfonate (MMS). They could also occur from endogenous 
compounds like S- adenosylmethionine (SAM) (54). These compounds can create O-alkylated 
and N-alkylated adducts which is toxic to the cell (54). Although lesions of these types could 
be repaired by the BER pathway, two direct repair routes exist: AGTs reverse O6- alkylated 
guanins and AlkB reverse N-alkylated lesions (53).   
4.2. Mechanisms and functions of chromatin remodeling 
The size of the eukaryotic genome requires tight packing and organizing of the DNA (57), 
while at the same time ensuring proper accessibility of genes and regulatory elements. The 
INO80 is another important family of chromatin remodeling proteins. INO80 is different from 
SWI/SNF and ISWI in several ways. First, the ATPase subunit of INO80 has a spacer region 
;A
DNA is wrapped around histone proteins that together make up the nucleosome which is the 
basic unit of chromatin (57,58). Nucleosomes are positioned on the DNA in an ordered way 
and they are typically depleted at many enhancers, promoters and terminator regions (59,60). 
The positioning bias varies between organisms and is found to be more pronounced in yeast 
than in humans (61). The accessibility of chromatin also varies across the genome (62) and is 
dependent on the histone proteins and how they are modified (63-65). 
Chromatin remodeling proteins are often defined as proteins that can allow access to DNA 
bound to nucleosomes by altering the nucleosome structure (66). Remodeling proteins gained 
increased interest when it was shown that these proteins together with other modifying 
complexes could add and remove modifications on the histone proteins and thereby affect 
transcription and subsequently the expression of genes (67,68). One common feature for the 
remodeling proteins is the ATPase domain that enables hydrolysis of ATP which generates 
the energy necessary to alter histones (69). The chromatin remodeling proteins interact with 
nucleosomes in at least two ways, either by sliding nucleosomes along the chromatin or by 
exchanging histones within nucleosomes (70). In both cases the result is recruitment of DNA 
binding factors (70).   
Several families of chromatin remodeling proteins are described, with the main eukaryotic 
being: SWI/SNF, ISWI, NURD/Mi-2/CHD, INO80 and SWR1 (71). The most studied of 
these are the SWI/SNF, the INO80 and the ISWI remodelers. They share a very similar 
ATPase domain that probably have the same biological function (71), and a catalytic domain 
close to the C termini that varies between the two families (Fig. 1). The catalytic domain of 
the SWI/SNF remodelers is the bromodomain that binds acetylated histone tails, whereas the 
ISWI remodelers have two different catalytic domains, known as SANT and SLIDE (72). 
The ISWI remodelers have a special role in DNA replication which involves ordering of 
nucleosomes after the chromatin has been opened (73). The main function of the ISWI 
remodelers seems to be in ordering nucleosomes to promote transcriptional repression 
(74,75). This is in contrast to the SWI/SNF remodelers that promote transcription by 
disordering nucleosomes to facilitate transcription factor binding (76). Although several 
studies have shown that ISWI remodelers are responsible for nucleosome ordering (77) and 
SWI/SNF remodelers for nucleosome disordering (78), their role can vary depending on 
chromatin context (71).  
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that split the ATPase domain, a feature shown to be important for protein-protein interactions 
(79). Second, in contrast to SWI/SNF and ISWI that do not exhibit helicase activity in spite of 
have a helicase domain, the S. cerevisiae INO80 has actually been shown to exhibit ATP-
dependent DNA helicase activity (80). The INO80 proteins are responsible for the 
organization of nucleosomes around the promoter of actively transcribed genes (81) and are 
shown to be important transcriptional regulators. Indeed, from studies in yeast and plants, it 
has been shown that INO80 is responsible for regulating as much as 20% of the genes (81-
83). The transcription factor Yin Yang 1 (YY1) is one of the subunits of INO80 and is 
believed to be responsible for at least some of the recruitment of INO80 to promoter regions 
(84). Recruitment of INO80 to promoter regions is dependent on transcription factors, and the 
transcription factor Pho4p, which binds the PHO5 promoter, is the central factor in the 
recruitment (85). The regulation of the INO80 complex itself is important in the adaption and 
response to external stimuli and signaling. Like most proteins, INO80 can be regulated 
through post-transcriptional modifications of its subunits (86). As an example, when the cell 
is responding to damage, INO80 is phosphorylated at the Ies4 subunit by the kinase ATM 
(86), causing the protein to become activated. Another way of regulating the activity of 
INO80 is through inositol lipids which also regulate the activity of for ISWI and SWI/SNF 
(87). When the inositol polyphosphate kinase Arg82 exerts its function on INO80, INO80 
dissociates from the promoters it binds to and ultimately reduces the expression of associated 
genes (87).  
 Figure 1: ISWI and SWI/SNF remodelers share a similar ATPase domain which is also found in INO80.
However, here it is separated by a spacer region. The ISWI remodelers contains a SANT and SLIDE domain at
the C-terminal that probably function in binding histone tails and DNA linkers. The SWI/SNF remodelers
contain a bromodomain in its ATPase subunit that binds acetylated histone tails. 
In response to DNA damage, chromatin opens up to increase the access for the repair 
machinery (100). In the case of double strand breaks, several proteins from the 
phosphatidylinositol 3-kinase-like family of kinases including ATM, ATR, and DNA–PK are 
important (101). Ataxia telangiectasia mutated (ATM) is a serine/threonine protein kinase 
protein responsible for the relaxation of chromatin (94) and is induced in response to DNA 
damage (102). One of the substrates for ATM is KAP-1 (94,103). ATM is thought to work 
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Several lines of evidence have shown that INO80 is important for transcription regulation 
(81). Moreover, recent reports show that INO80 also contributes to DNA replication, and 
increased expression of INO80 in S phase has been observed (88-90). Experiments have 
shown that INO80 mutants are highly sensitive to replication-blocking agents, suggesting that 
INO80 is directly involved in chromatin organization at the replication fork (66,91). 
Moreover, INO80 mutants show severe problems in resuming DNA replications after 
treatment with methyl methanesulfonate (MMS), a well-established DNA replication blocking 
agents. This observation has been explained by decreased levels of the ubiquitinated forms of 
PCNA, and that INO80 is required for PCNA ubiquitination through its ATPase and 
remodeling properties (92). However, it is not known if this is a direct effect of INO80 or if 
the effect is indirect through the recruitment of other proteins by INO80 (66).  
INO80 and many of the other remodeling proteins have received increased interest in the field 
of DNA repair. The following section describes some of the main mechanisms of how 
chromatin is reshaped and altered by remodeling proteins in response to DNA damage. 
4.3. Chromatin remodeling and DNA repair 
There has in recent years been a strong focus in the field of DNA repair to understand how 
DNA lesions in closed chromatin are made accessible for the repair machinery (93). Damages 
that are formed in heterochromatin are thought to be processed slower than those formed in 
euchromatin (94,95), and the damage response itself is dependent on the chromatin landscape 
within which the damage occurs (96-98). ATP-dependent chromatin remodeling enzymes are 
thought to play a key role in organizing the chromatin before and after DNA repair (99). 
These enzymes are able to use energy derived from ATP hydrolysis to change chromatin 
structure. The enzymes can shorten or extend the linker DNA between nucleosomes, load or 
remove nucleosome from the DNA or replace histone variants on the nucleosomes (99).  
of both Cyclobutane Pyrimidine Dimers (CPDs) and 6–4PPs (120).  The INO80 complex has 
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through the phosphorylation of KAP-1, which perturbs heterochromatin when the interaction 
between KAP-1 and heterochromatin is diminished (94,104).  Although ATM has been shown 
to play a central role in the repair of at least a subset of DSBs (105), some controversies exist 
on its importance (106). The requirement for ATM seem to correlate with chromatin 
complexity and in heterochromatin regions the cell is unable to access and repair damaged 
DNA unless ATM is active and phosphorylates KAP-1 (94).  
The INO80 complex is recruited to DSB, suggesting a role in direct repair. Specifically, in 
budding yeast the INO80 complex is recruited to a 1.6 kb region around the DSB and this 
recruitment is shown to be guided by the phosphorylated form of H2AX (γ-H2AX) (107). The 
function of INO80 in DSB include both non-homologous end-joining and homologous 
recombination  (101), which are the two mechanisms the cell uses for DSB repair. A more 
detailed mechanism was described by Tsukuda et al. when they showed that absence of 
histone removal at DSB regions resulted in delayed recruitment of the repair protein Rad51. 
They hypothesized that INO80 was involved in this process through its regulation of H2A 
(108).  
The role of chromatin remodeling proteins in DNA repair goes beyond the repair of DSB. 
Chromatin remodeling genes are activated in response to UV irradiation (109-112). UV 
damage is repaired primarily by nucleotide excision repair (NER) (113).  The NER pathway is 
divided into two pathways: global genomic repair (GGR), which works genome wide and 
transcription-coupled repair (TCR), which repairs lesions in regions actively transcribed by 
RNA pol II (114). The cell faces the same challenge for UV induced damage as for DSBs in 
recognizing and accessing the damaged site. In response of UV damage the DNA is 
unwrapped from the histones allowing repair proteins to access (115). As expected, TCR is a 
more rapid process than GGR, possibly impart of the open chromatin state around the 
transcription site which leads to better recognition and access to the damage (116). It has also 
been shown that Histone 2A, 3 and 4 are ubiquitinylated at the sites of damage, causing a 
more relaxed DNA-histone interaction (117,118). In eukaryotic cells these modifications are 
achieved by the DDB1–DDB2 complex, which also recognizes the damage (117). In addition 
to the DDB1–DDB2 complex, both the SWI/SNF and INO80 chromatin-remodeling complex 
have been reported to promote removal of UV-generated lesions in the NER pathway 
(119,120). The SWI/SNF complex is shown to contribute to removal of pyrimidine(6-
4)pyrimidone photoproducts (6–4PPs) (119,121), whereas INO80 is involved in the removal
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also been shown to contribute to removal of UV lesions in non-transcribed regions through 
GGR (120).  
Histone acetylation is another mechanism that is regulated in response to UV damage 
(122,123). In humans and yeast, histone 3 (H3) acetylation is increased after UV damage and 
correlates with NER activity (122,123). Since H3 acetylation in general is associated with 
open chromatin this modification is thought to facilitate the access of NER proteins and 
increase repair (109).   
In summary, the interplay between DNA repair genes and chromatin remodeling proteins is 
highly complex and an essential factor for maintaining genome integrity. The remodeling 
proteins are highly conserved during evolution and are critical for repair of various lesions 
and for repair pathways function, including MMR, BER and especially DSB repair.  
4.4. Gene regulation by histone modification and Polycomb 
proteins 
An important group of chromatin remodeling proteins is the Polycomb group (PcG) proteins. 
The PcG proteins were discovered in Drosophila melanogaster in 1978 in a famous Nature 
paper by Edward B. Lewis, which later resulted in the Nobel prize (108). Lewis et al. showed 
that PcG regulates a set of genes, which was later known as the Hox genes, during embryonic 
development in the fly. The PcG proteins are responsible for forming the H3K27-me2/me3 
marks on the histone proteins (124). The PcG proteins are part of a large Polycomb repressive 
complex (PRC), which are separated into two sub-complexes PCR1 and PCR2, containing 
several proteins with distinct functions (124). PCR1 has four main subunits, Cbx, Ring1, Phc, 
and Bmi1/Mel18 (reviewed in (125)). One of the important features of the Cbx subunit is the 
ability to bind di- or trimethylated K9 and K27 lysine residues on the H3 peptides (126). 
PCR2 has three main subunits, Ezh2/Ezh1, Eed and Suz12 and various combinations of these 
exist (126). One very important feature of PCR2 is its ability to methylate H3 lysine 27, and 
PCR2 may be the only protein complex that are able to produce di- and tri-methylated H3 
lysine 27 (127). Since the Cbx subunit of PCR1 is able to bind  di- and tri-methylated H3 
lysine 27, a model has been proposed where PCR2 methylation is required for PRC1 
recruitment to target genes (127). Although PCR1 and PCR2 have distinct subunits, mutations 
in either of the protein complexes affect the other protein complex, indicating that PCR1 and 
PC2 are functionally inter-dependent under certain conditions (128,129). 
MicroRNAs are small ~22 nt RNA molecules that function in a single-stranded form to 
repress mRNAs (144).  In humans, almost 2000 unique miRNAs have been discovered and 
deposited in public databases (145), and it has been predicted that more than 60% of the 
human genes are conserved miRNA targets (146). MicroRNAs were first discovered in the 
model organism of nematodes, Caenorhabditis elegans, as a regulator of developmental 
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The PcG proteins were first identified as proteins that regulate cell fate decisions at different 
stages of development by interfering with the Hox genes. Later it was shown that PcG 
proteins are recruited to genes involved in other processes, for instance genes associated with 
cancer (130). Several groups have shown that proliferation is altered in stem cells and normal 
cells as a result of the interaction between PcG and the cyclin-dependent kinases CDKN2B 
and  CDKN2A, encoding the tumor suppressors INK4B, INK4A and ARF (131,132). These 
genes are associated with the Rb and p53 pathways, two critical G1/S phase regulators 
(reviewed in (132,133)). Genes targeted by PcG have a much higher probability to be silenced 
by DNA methylation compared to other genes (134-136), and in fact, p53 and Rb are often 
epigenetically silenced by DNA methylation in cancer (137). At least two models exist that 
explain the increase in DNA methylation of PcG target genes. One scenario is that PcG 
proteins get up-regulated in cancer, leading to recruitment of DNA methyltransferases and 
increased methylation. This is supported by the observed up-regulation of PcG in many 
cancers (138). However, this model is challenges by the fact that cancer cells in general show 
increased proliferation and the expression of many of the PcG proteins correlates with 
proliferation (130). Another model has therefore been proposed which tries to explain the 
increased silencing of PcG targets by de-regulated PcG co-proteins (130). In this model 
transcription factors are proposed to play a central role and especially the CFTF family of 
transcription factors, but also other families like Hox, Sox, Runx, Fox, Pax and Gata (130). 
Much of the complexity in eukaryotes is attributed to gene regulation by transcription factors 
(139); however, a detaled description of their role is beyond the scope of the present thesis. 
In 2006, a paper was released describing a 2.2kb long non-coding RNA (lincRNA) termed 
HOTAIR, that interacts with PCR2 and presumably works as a scaffold for histone 
modification enzymes to bind DNA or as a guide RNA to recruit PcG to their target genes 
(140-142). This discovery, and the discovery of lincRNAs in general, has been very important 
in the understanding of how proteins are guided and bind to specific regions in the genome 
(reviewed in (143)).  
4.5. MicroRNA biology and function 
After the pri-miRNA has been processed by the Microprocessor complex (or the splicing 
machinery for mirtrons), it leaves a precursor miRNA of about 70 nts in length that are 
exported from the nucleus to the cytoplasm (155,156). The export is mediated by Exportin-5 
and its co-factor Ran-GTP (157). Once in the cytoplasm, the RNase III protein Dicer 
recognizes the terminal loop in the pre-miRNA and removes it to leave a double-stranded 
miRNA duplex. The precise mechanism for Dicer cleavage is not fully known. However, at 
least three models have been established trying to explain this process. Two models are that 
Dicer measures a fixed distance (usually 22 nts) from either the 3' end overhang (3' counting 
rule) (158,159) or from the 5' phosphate group (5' counting rule) (160) and thereby determine 
the cleavage site. A third model is that Dicer recognizes the terminal loop in addition to the 
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timing (3,147). Later, a large number of studies have demonstrated the importance of 
miRNAs in a wide range of biological processes (148,149).  
MicroRNAs are transcribed in the nucleus by RNA polymerase II into long primary 
transcripts (pri-miRNA) that contain one or more miRNA hairpin structure (144) (Fig. 3). The 
hairpins have a characteristic structure with a double stranded stem and a terminal loop, both 
of which serve as recognition features for proteins in the maturation process (150,151). 
Mechanistically, a protein complex called the Microprocessor, consisting of the RNase III 
family nuclease Drosha, and its co-partner DGCR8, uses the flanking ssRNA segments in the 
pri-miRNA to bind and cleave the pri-miRNA approximately 11 nts the stem-ssRNA junction 
(152) (Fig. 3). DGCR8 is proposed to function as an anchor that measures the correct distance 
from the stem-ssRNA junction (152). The Microprocessor requires at least 40 nts on each side 
of the hairpin duplex for proper processing of the pri-miRNA (153). A long-standing question 
in miRNA biogenesis has been how the cell is able to distinguish an authentic pri-miRNA 
from other types of hairpins transcribed in the nucleus. Bartel et al. reported three possible 
primary-sequence determinants in non-nematode pri-miRNAs, including a SRp20-binding 
motif (CNNC) down-stream of the pri-miRNA hairpin, a UGU or GUG motif in the terminal 
loop and a basal UG motif (151). They found that 79% of the conserved human miRNAs 
contained one of the three pri-miRNA determinants, indicating that they have a function in 
pri-miRNA recognition.  
In 2007, Bartel et al. described an alternative to the canonical pri-miRNA processing in which 
intronic regions get transcribed into pri-miRNA like molecules that enter the miRNA-
processing pathway without cleavage by Drosha. They termed these molecules “mirtrons” 
(154). Instead of using Drosha, mirtrons get processed by the endogenous splicing machinery. 
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3'/5' ends and uses both features to determine the cleavage site (161). One strand of the 
miRNA duplex is subsequently incorporated into the RNA-induced silencing complex (RISC, 
or miRISC for miRNA-containing RISC), where it binds to a protein in the AGO protein  
family. The strand that is not incorporated into RISC is usually degraded by nucleases in the 
cytoplasm, but can sometimes act as a functional miRNA (162). Ago2 has the ability to cleave 
miRNA precursors to create mature miRNA in the absence of Dicer, however this is regarded 
as a rare exception (163,164). Once the mature miRNA is loaded into RISC is has the ability 
to target and repress complement mRNA sequences. The targeting itself is a complex 
mechanism that involves base-pairing between a specific part of the miRNA and usually the 3' 
untranslated region (3' UTR) of the target mRNA. Illustration of miRNA directed repression 
is shown in figure 4. 
Figure 3: MiRNA biogenesis pathway. A detailed description of the different steps in the
pathway is found in the text. 
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Figure 4: MicroRNA mediated gene repression. A miRNA (blue) incorporated in the silencing complex pairs to 
a target mRNA (red) together with an Argonaute protein (Ago) to direct mRNA repression. If the base-pairing 
between the miRNA and the targeted mRNA is perfect or near perfect the repression can occur through mRNA 
cleavage (left side in figure). If the miRNA binds the targeted mRNA with only partial complementarity, the 
repression will not involve Ago-mediated cleavage. In this second process, the miRNA binds the mRNA using a 
short sequence at the 5' end of the miRNA called the miRNA seed. This type of repression involved recruitment 
of factors that causes translational inhibition (thin repressive lines) or, more common, destabilization of the 
mRNA followed by shortening of the poly(A) tail and degradation (thick repressive lines). 
4.5.1. MicroRNA targeting 
The average miRNA is 22 nts in length (165) and contains a region of 6 nts at the 5' end 
called the seed region that is critical for pairing to target mRNAs (166). David Bartel et al. 
showed that >60% of human protein-coding genes have conserved binding sites for miRNAs 
in their corresponding mRNAs (146). The pairing between miRNAs and mRNAs is generally 
divided into four main binding sites; a 6mer, two 7mers, and one 8mer (Fig. 5) (166). The 
6mer is a perfect 6nt match between nucleotides 2-7 of the miRNA and the mRNA. The two 
types of 7mer sites are 1) a seed match with additional paring at miRNA nucleotide 8 in the 
miRNA 2) a seed match followed by an A at target position 1. The strongest binding sites are 
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8mers which comprises the seed match and both additional paring at miRNA nucleotide 8 in 
the miRNA and an A at target position 1.  
Since a 6mer match is expected to occur once every 4,096 nucleotides in the genome, clearly 
other factors must be involved in determining a functional miRNA site. Several additional 
structure and sequence features are shown to influence the repression by miRNAs. For 
instance, closely spaced sites result in more down-regulation of mRNAs compared to if the 
sites are further apart (166,167), and similar if there is additional pairing at nucleotides closer 
to the 3' end of the miRNA, called 3′-compensatory pairing (166). 3′-compensatory pairing is 
thought to compensate for mismatches in the seed region and enhance recognition of mRNA 
targets (166). The miRNA seed region has strong affinity of target mRNAs, mainly as a result 
of how the Ago proteins are pre-organizing the 5′ region of the miRNA to favor Watson–
Crick pairing in this region (162).  
David Bartel and his group described another type of pairing between miRNAs and mRNA 
involving the central region of the miRNAs (168). They showed that in the absence of perfect 
seed pairing and 3’-compensatory pairing the miRNA could bind to an mRNAs using 11-12 
nucleotides in the central region of the miRNA. Despite being less conserved than the 5’ and 
3’ region of the miRNA, Bartel et al. showed that “central pairing” is indeed functional in 
reducing mRNA and protein abundance.  
General sequence features have been shown to increase target site efficiency. As an example, 
target sites in regions with high AU-content are more efficient than those residing in other 
regions (166). Furthermore, target sites positioned away from the central region of the 3’ UTR 
show more efficient repression, especially if the 3’UTR is long (166).  
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A recent study by MacRae et al. uses crystal structures of human Ago2 to explain the 
structural basis for miRNA targeting (169). By crystalizing Ago2 bound to a miRNA with and 
without target mRNA, they showed that miRNA targeting takes place in a stepwise 
mechanism. First, the guide nucleotides 2-5 are exposed to the target mRNA. This initial 
targeting creates a conformational change in the miRNA that exposes nucleotide 2-8 and 13-
16 for extended target recognition. Specifically, they show that seed pairing leads to a 
rearrangement of the 3’ end of the miRNA, increasing the interaction between the miRNA and 
the mRNA target. These results explain the conservation pattern previously observed for 
miRNA targets (170). It also explains why miRNAs sometimes have pairing at the 3’ end, as 
identified by Bartel et al. (166). 
4.6. The Argonaute proteins 
Argonaute proteins (Ago proteins) are the backbone proteins in all small RNA-guided 
silencing processes. They are conserved in all examined eukaryotes, with the exception of 
Saccharomyces cerevisiae, which do not possess small RNA regulation (171). The Ago 
Figure 5: Four types of miRNA sites. A detailed description of the sites is 
found in the text. 
One of the great mysteries in small RNA biology has been how the Ago proteins choose the 
correct strand in the RNA duplex and how the strand is loaded onto the Ago proteins. One 
approach has been to examine the stability of the duplex, and the strand with less stable 5′ end 
is shown to be preferentially loaded (177), a phenomenon known as “the asymmetry rule” 
(178). Furthermore, it has been reported that Ago1 and Ago2 both possess ATP-independent 
strand-dissociating activity of miRNA duplexes, a function reminiscent of RNA chaperone 
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proteins are the direct binding proteins for small RNAs and have their names after the squid 
like phenotype of Arabidopsis thaliana Ago1 mutants (172). The mammalian genome 
contains four homologous Ago genes: Ago1-4 (173). The four Ago genes have diverged from 
a common ancestral Ago gene and three of the genes (Ago1 and Ago3-4) are found as tandem 
repeats in the same human chromosome, while Ago2 is located on a different chromosome 
(173).   
The Ago proteins are characterized by four protein domains; N (amino-terminal); PAZ 
(PIWI–ARGONAUTE–ZWILLE); MID (middle); and PIWI (Fig 6). The PAZ domain 
contains a small RNA binding pocket that binds the 3’ end whereas the MID domain binds the 
5′ end of the small RNAs by interaction of the 5' terminal base of the RNA with a conserved 
tyrosine residue in the protein (174). The N domain is required for correct loading of small 
RNA and plays a role in unwinding the small RNA duplex (175). High resolution crystal 
structure of human Ago2 and miR-20a showed that the miRNA is bound at both ends by the 
MID and PAZ domains and that the binding of a miRNA increases the stability of the Ago 
protein by locking it in a stable conformation (176). The crystal structure revealed that all 
domains in the Ago2 protein are interacting with the miRNA, which is probably the reason 
why the stability of the protein is increased in the presence of a miRNA (176).  
Figure 6: Position of domains in the Argonaute protein (human Ago2 is shown here). All Ago proteins 
share two domains:  The PAZ domain (yellow) and the PIWI domain (orange). The PAZ domain
contains a specific binding pocket that fixes the two-nucleotide 3’ overhang.  The show high degree of
homology to RNase H and this domain is referred to as the slicer domain in human Ago2. The MID
domain lies between the PAZ and the PIWI domain and binds the 5' phosphate group of small RNAs. 
The MID domain is also shown to be important for the interaction between Ago and other proteins.  
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activity (179). Ago2, which is the only member of the Ago protein family that possesses 
catalytic activity (180), is able to cleave perfectly paired siRNA duplexes and more rarely also 
miRNA duplexes (181). The catalytic property of Ago2 enables rapid dissociation of the 
passenger strand which could have important implications for small RNA activity and target 
repression by rapidly activating RISC (182-184). 
Controversies still exist whether subpopulations of miRNAs preferentially bind to different 
Ago proteins. Some reports show that this is indeed the case (185), and others show that 
miRNAs bind randomly to Ago proteins (186,187). One report by Meister et al. indicates that 
the four Ago proteins prefer miRNAs with specific lengths (186). Specifically, they show that 
Ago2 prefers miRNAs of length 22, whereas Ago1 and Ago3 have a tendency to bind 
miRNAs of length 23 and 24 nts. Such length preferences were studied in more detail by 
Makeyev et al. who showed that Ago2-loaded miRNAs undergo efficient 3′-terminal 
trimming to yield miRNAs 1-2 nts shorter than those loaded onto the other Ago proteins 
(188). They further showed that a specific residue in the PAZ domain of Ago2 provides the 3' 
trimming property, possibly by creating a looser interaction between the miRNA 3' end and 
the protein, making the miRNA 3' end more accessible to a trimming exonuclease. Although 
miRNAs are diverse with regard to sequence, most miRNAs tend to start with A or U at the 5’ 
end (176,189,190). Crystal structures of the Ago2 MID domain in complex with nucleoside 
UMP or AMP (nucleotide U or A), revealed specific interactions between these two 
nucleosides and the MID domain, explaining the previously observed preference for A and U 
at the 5’ end of the miRNA (191). In detail, they show that a conserved region in the MID 
domain, called the nucleotide specificity loop, is responsible for the interaction with the 
nucleotide base, and that this region is important for the base preference and sorting of small 
RNAs to the Ago proteins. Several studies have demonstrated the importance of the 5’ 
nucleotide in small RNAs. In T. thermophiles, the miRNA 3’ end is released from the Ago 
PAZ domain when the miRNA binds a target mRNA, whereas the miRNA 5’ end preserves 
its interaction with the MID domain (192). In Arabidopsis thaliana, the 5′ nucleotide is 
functioning as a sorting signal for small RNAs to the different plant Ago proteins (193-195). 
Similar observations have been reported for flies for miRNAs associated with Ago1 and Ago2 
(189,196).    
The expression of the four Ago proteins varies between tissues and Ago4 in particular seems 
to be expressed in a limited number of tissues compared to the other Ago proteins (197-199). 
Moreover, the expression of Ago3 and Ago4 is generally lower than that of Ago1 and Ago2 
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(197). It is speculated that differences in codon distribution in the N-terminal region are 
responsible for the differences in expression, both at the protein and mRNA level (197). In the 
past few years, more studies on the function of the different Ago proteins have been 
conducted. We know that Ago proteins are involved in a wide range of cellular processes 
including transcription, alternative splicing and possibly also DNA repair (reviewed in (200)). 
Ago2 in particular appears to be indispensable in some processes. Studies in mice have shown 
that Ago2 is essential during early development (201,202) and necessary for the processing of 
miR-451 which plays an essential role in hematopoiesis (163,203). Moreover, changes in 
Ago2 expression during brain development is shown to influences miRNA activity (188). 
Taken together, much is known about the structure and function of the Argonaute proteins 
both in relation to small RNA regulation and other processes; however, there are still 
mechanisms far from fully understood. For example, how is the loading of small RNAs into 
the Argonaute proteins regulated, and how are the small RNAs dissociated from the protein to 
ensure rapid turnover in response environmental changes or during developmental transitions.  
4.6.1. Nuclear function of Argonaute proteins 
Argonaute proteins are present both in the cytoplasm and in the nucleus and that they have 
conserved functions in both compartments of the cell (204-207). Small RNAs in complex 
with Ago1 and Ago2 are shown to bind complementary regions in the DNA of promoters 
regions and transcription start sites (208). Sequencing of small RNAs bound to Ago1, Ago2 
and Ago3 shows that ~0.02% of the sequences map to promoter regions, most of which are 
associated with Ago1 (205). Ago1 is shown to interact directly with RNA polymerase II 
(205,209,210), particularly at promoters of actively transcribed genes marked with histone 3 
lysine 4 tri-methylation (H3K4me3) (205). In Drosophila, Ago2 localizes to euchromatin but 
not heterochromatin (211). While both Ago1 and Ago2 are actively transported into the 
nucleus, the nuclear role and localization are different between the two proteins. Ago1 mainly 
localizes to the nuclear interior, whereas Ago2 is found in the inner nuclear envelope 
(205,212).  
Several examples exist showing that particular miRNAs bind to promoter regions and act in 
transcriptional gene silencing (TGS). Ago1 was found to be enriched at the CCNB1 gene 
promoter and Ago1 together with the three miRNAs, miR-744, miR-1186 and miR-466d-3p 
induces the expression of CCNB1 (210). Several similar interactions are reported, for instance 
POLR3D silencing by miR-320 (213), PGR and IGSF1 silencing by miR-423-5p (214) and 
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CDKN1 activation by miR-373 (215). 
The miRNA miR-29b is shown to be primarily localized in the nucleus of cyclic cells (216). It 
was shown that a hexanucleotide 3′ terminal motif (AGUGUU) of miR-29b specifies cellular 
localization of this miRNA and that Ago2 and Importin8 are responsible for the import (216). 
The exact role of miR-29b in the nucleus is not known; however, Hwang et al. speculated that 
it might be involved in regulating transcription or splicing, in addition to or instead of 
canonical miRNA gene silencing (216). Ago2 associated small RNAs are previously shown to 
be involved in alternative splicing. Corey et al. showed that small RNAs recruit Ago2 to pre-
mRNA transcripts and thereby promote intron/exon exclusion (217). Moreover, the 
endogenous non-coding RNA MALAT was shown to interact with Ago1 and Ago2 (218) and 
to regulate alternative splicing (219).  
Another surprising function of Ago proteins was revealed by Qi et al. who showed that 21-
nucleotide small RNAs (later termed diRNAs) are transcribed around sites of DSB, both in 
plants and animals (9) and are necessary for proper DSB repair together with Ago2. They 
further showed that knock-down of Ago2 reduced DSB repair, indicating that Ago2 is 
important for diRNA function. Subsequently, it was shown that diRNAs are restricted to 
homologous recombination (HR) by recruiting the repair protein Rad51, and that the catalytic 
activity of Ago2 is required for efficient DSB repair (220). The exact mechanism of diRNAs 
is not fully known. However, these findings reveal a novel function for Ago2 and small RNAs 
in the nucleus.  
4.7. The eukaryotic cell cycle 
The cell cycle, or cell division cycle, is separated into distinct phases that each are 
characterized by a specific molecular process (reviewed in (221)). These phases are Growth 
phase 1 or Gap phase 1 (G1); DNA synthesis phase (S); Growth phase 2 or Gap phase 2 (G2) 
and Mitosis (M). Cells that are not dividing are often said to be in G0, a state of quiescence. 
Based on the physical appearance in the microscope the cell cycle is divided into two broader 
phases: interphase and mitosis. Mitosis only constitutes about 5% of the cell cycle time, 
which implies that most of the time the cell is in interphase (222). During mitosis the cell 
separates the chromosomes and eventually divides into two daughter cells (cytokinesis). The 
length of the cell cycle varies largely between cell types in culture, but the average cell length 
tend to follow the circadian clock with a duration of about 24 hours (223,224). The longest 
cell phase is usually G1 phase, during which the cell prepares for DNA replication by 
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producing the required proteins and enzymes. During S phase the cell duplicates its DNA and 
as it enters G2 phase the cell contains twice as much DNA as in G1 phase. Usually the cell 
proceeds rapidly through G2 phase and enters mitosis 2-4 hours after leaving S phase. The 
resulting two daughter cells will then enter G1 phase and start a new cell cycle given the right 
conditions (223).   
4.7.1. Regulation of the eukaryotic cell cycle 
Normal dividing cells are subject to complex regulation at multiple steps in the cell cycle. 
This regulation is closely linked to sensing of damaged DNA which activates DNA damage 
response (DDR) pathways. Most lesions to DNA are repaired by one of the many DNA repair 
pathways (reviewed in (10,225)). In case of severe damage, the cell may enter the pathway of 
programmed cell death called apoptosis (226). 
Transitions between the different cell cycle phases are critical points and therefore highly 
regulated (227). For example, a cell that contains damaged DNA should not enter M phase, as 
the damage will then be propagated to the next generation of cells. Cell cycle transitions are 
irreversible. This means that once the cell commits to enter a new cell cycle phase it cannot 
return to the previous phase, even when the transition signal disappears (228). This 
irreversibility is controlled by a feedback system that prevents cyclin resynthesis (229). The 
eukaryotic cell has three irreversible cell-cycle transitions: G1–S, G2–M and M–G1. At each 
transition, specific cyclin-dependent kinases (CDKs) are ubiquitinated and degraded (230). 
CDKs play a central role in regulating transitions between cell cycle phases (227). The CDKs 
are highly conserved during evolution, indicating an indispensable role in regulation. The 
mammalian CDK family includes 13 proteins, but only CDK1, CDK2, CDK4  and CDK6 are 
directly involved in cell cycle regulation (Fig. 7) (reviewed in (231)). As the name indicates, 
CDKs are in complex with cyclins. Type-D cyclins (D1, D2 and D3) sense mitogenic signals 
and form complex with CDK4 and CDK6 during G1 phase. These complexes are responsible 
==
for inactivation of the Retinoblastoma-associated protein (Rb), resulting in cyclin-E activation 
and CDK2/cyclin-E complex formation (232). In late S phase, CDK2 is activated by cyclin 
A2 which drives the cell from S phase to M phase. At the end of interphase, A-cyclins 
activate CDK1 thereby facilitating M phase progression (233). At the G2–M transition, the 
nuclear kinase Wee1 is also degraded, leading to CDK1 activation (234). During mitosis the 
A-cyclins are degraded, causing CDK1–cyclin B complexes to be formed, which is part of the 
final regulation that drives the cells through cell division (233). The degradation of mitotic 
cyclins is ubiquitin-mediated and controlled by the anaphase promoting complex (APC), an 
E3 ubiquitin ligase.  
Based on the mechanism described above, CDKs may seem essential for cell cycle 
progression. Surprisingly, knock-out of selected CDKs in mouse models leads to 
developmental defects, but does not lead to loss of cell cycle division (235,236). Moreover, 
mouse embryos lacking interphase CDKs develop normally until mid gestation (237). These 
Figure 7: Overview of the human cell cycle and the main proteins involved in regulating the transition
between phases. Cell cycle phases are indicated as S: S phase; M: Mitosis; G1: G1 phase and G2: G2 phase. 
Since CDKs are dys-regulated in many cancers, either directly or indirectly through loss of 
inhibitors, one might ask if the tumors require CDKs to maintain their proliferating nature. 
Some tumor cell lines depend on interphase CDKs, whereas others seem to divide without 
CDK activity. For instance, colon carcinoma cell lines do proliferate in the absence of CDK2, 
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observations indicate that CDKs are required for some cell types at some developmental 
stages, but not for all cellular lineages.     
4.7.2. When the regulation goes wrong 
More than 100 genes are classified as so-called cancer predisposition genes (CPGs) (238). 
There is no clear definition of CPGs; however, these are generally genes that increase the risk 
of cancer development if mutated. CPGs are often associated with central cellular processes 
such as DNA repair and cell-cycle regulation, but also include genes in the chromatin-
remodeling pathway.  
Examples of proteins that are implicates in many cancers are CDKs. As described in the 
section above, CDKs control critical regulatory pathways in the cell cycle. A number of 
studies have shown that dys-regulation of CDKs is contributing to tumor development and 
tumor progression (reviewed in (239,240)). CDK activity is controlled by a wide set of 
inhibitor molecules, including the INK proteins (INK4A, INK4B, INK4C, INK4D) and the 
Cip and Kip proteins (p21, p27 and p57) (231). Proliferating stem cells are regulated by these 
inhibitors (233). Specifically, the INK proteins p21 and p27 are required to control self-
renewal of neural, intestinal and hematopoietic progenitors, and similarly the INK proteins 
INK4A, INK4B and INK4C regulate self-renewal of hematopoietic, brain, lung and 
pancreatic stem and progenitor cells (reviewed in (233)).  
The dys-regulation of CDKs can be either through overexpression of CDKs or loss of activity 
from CDK inhibitors (239). Mice resistant to the INK4 inhibitor develop hyperplasia in the 
same cells that require CDK4, as well as other tumor types. CDK4 is over-expressed in many 
tumors, including gliomas (241), sarcomas (242), breast tumors (243) and in uterine cervix 
cancer (244). Similar, CDK6 expression is elevated in squamous cell carcinomas and gliomas 
(245) and lymphoid tumors (246). Furthermore, deletions in the 9p genomic region, which 
overlaps with several cell cycle gene loci, including the INK4 family of inhibitors 
(p16/CDKN2A and p15/CDKN2B), are among the most frequent alteration in cancer (239). 
In lymphoid tissues, deletions in this regions are often linked to non-functional V(D)J 
recombination, an important step in immunoglobulin production in the immune system (247).  
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whereas cells from glioblastomas and osteosarcomas are sensitive to reduced CDK2 levels 
and proliferation is inhibited (248,249). In CDK4-deficient mice, resistance to mammary 
tumor development is observed (250). Similarly, mice lacking cyclin D, one of the co-factors 
of CDK4, are also resistant to breast tumors (251).  
Drugs developed to target CDKs are generally less specific and they often target several 
similar proteins at the same time (239). Less specific drugs have higher anti-proliferative 
effects compared to more specific drugs with single targets (239). 
Several transcription factors are dys-regulated in cancer, many of which promote metastasis 
(reviewed in (252)). Transcription factor c-Myc is predicted to target 15% of human genes, 
many of which are genes controlling cell cycle and apoptosis. C-Myc is classified as an 
oncogene and is very often found to be up-regulated in cancers in addition to promote 
metastasis (253).  Members of the ETS family of Transcription factors (comprising more than 
30 genes in humans (254)) are also commonly dys-regulated during tumor development. The 
expression of several members of the ETS family frequently correlate with tumor 
aggressiveness (252) and is elevated in migratory cells (254). Another large group of 
transcription factors are the forkhead box (Fox) proteins, with at least 41 proteins identified in 
humans (255). The number of Fox protein genes is correlated with tissue complexity of 
organism during evolution and the function of the different Fox proteins varies largely 
(reviewed in (255)). The FOXM1 transcription factors are positive regulators of G1/S and 
G2/SM cell cycle phase transition (255). Opposite, FoxO inhibit cell cycle progression (255) 
and deletion of FoxO is associated with cancer-predisposition (256). Moreover, FoxP, another 
Fox family member, is crucial for development of the immune system and is linked to hyper 
proliferative disorders in the immune cells (257). The Fox proteins are also regulating cancer 
progression and have therefore been suggested as potential prognostic markers (255). 
Specifically, FOXC1 and FOXC2 are responsible for activating essential growth factors 
during vascular development (258), and FOXO1 is important for angiogenesis during 
embryonic development in mouse (259). The NF-κB family of transcription factors is also a 
central player in cancer. They are in complex with other transcription factors such as p53, 
ETS and STAT, and have important roles in regulating inflammation and the immune system 
(reviewed in (260)). NF-κB has at least two main functions in relation to cancer. It is part of 
the immune system that targets cancerous cells, and functions as an oncogene when dys-
regulated in cancer cells (260). Tumor suppressor p53 (or TP53 for gene name) is one of the 
hallmark tumor suppressor genes. The p53 protein is controlling cell cycle progression at the 
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transition between G1 and S phase and initiates apoptosis if damaged DNA is not repaired. 
Most mutations affecting TP53 alter its wild type function, leading to loss-of-function. 
However, some studies have reported gain-of-function mutations leading to increased 
mutation rate and metastasis.  As mutations in TP53 rarely affect its transcriptional domains, 
it is believed that mutated p53 still binds to DNA to alter gene expression, often in an 
unfavorable way for the cell. However, whereas several reports show that TP53 is mutated in 
cancer (reviewed in (261)), the exact mechanism of its function and the network of proteins 
that are involved around p53 is still not fully elucidated (262), which is why it is still 
frequently studied. 
4.8. MicroRNAs and the cell cycle 
The first hint about the involvement of miRNAs in cell cycle regulation came from a study on 
the miR-15-16 cluster showing that these miRNAs have anti-proliferative properties and that 
they were deleted in more than half of chronic lymphocytic leukemia (CLL) patients (263). 
The mapping of miR-15 and miR-16 showed that they were located at the chromosomal 
region 13q14.3, a region often altered in CLL and other cancers (264-267). Subsequently, the 
miR-15-16 cluster was shown to be deleted or down-regulated in a large number of cancers 
and to regulate critical cell cycle genes required for normal proliferation (reviewed in (268) 
and (269)). In the years following the miR-15-16 discoveries, many other interactions 
between cell cycle genes and miRNAs were described. The sections below review some of 
these interactions and describe the importance of miRNAs in cell cycle regulation. 
4.8.1. MicroRNAs and p53  
The p53 tumor-suppressor is part of a large network of proteins that sense DNA damage and 
various stress signals and respond by inducing growth arrest and promote apoptosis or DNA 
repair (270,271). Hannon et al. showed that the expression of the miR-34 family correlates 
perfectly with the expression of p53 and that these miRNAs were induced together with p53  
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when cells were treated with ionizing radiation (Fig. 8) (272). They further show that miR-
34a/b/c are all direct targets of p53. When over-expressing miR-34 they observed growth 
arrest at G1 combined with down-regulation of cell cycle genes, including cyclin E2 (CCNE2) 
and cyclin-dependent kinase 4 (CDK4). They concluded that p53 represses these genes by 
inducing miR-34. Other groups have reported similar results for other miRNAs, including 
miR-192, miR-215 and miR-145. Chau et al. showed that stress induced p53 causes up-
regulation of miR-192 and miR-215, and like miR-34, these miRNAs have several down-
stream targets important in cell cycle regulation (273).  p53 also represses the proto-oncogene 
c-Myc by binding to and inducing miR-145 which is as a direct target for c-Myc. In addition 
to its role in inducing specific miRNAs, Miyazono et al. described a fascinating role of p53 in 
enhancing the maturation of several miRNAs, including miR-16-1, miR-143 and miR-145, by 
interacting with the Drosha processing complex (274). This raises the possibility of a more 
global function for the interaction between p53 and miRNAs.   
4.8.2. MicroRNAs and the G1/S transition 
Cells have acquired a precise network of regulation at the G1/S transition to prevent abnormal 
cell proliferation and tumorgenesis. The commitment to enter S phase depends to a large 
degree on cyclin–CDK transcription and E2F transcription factors play a central role in this 
regulation (reviewed in (275) and (276)). E2F itself and many of the other G1/S associated 
genes are shown to be under regulation by miRNAs, either by direct targeting or through 
Figure 8: miRNA regulation by p53. Details on the interactions are found in the text. 
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suppression of important co-factors (reviewed in (277)). Embryonic stem (ES) cells that lack 
miRNA activity are shown to accumulate in G1 phase, and surprisingly, by introducing only a 
few miRNAs from the miR-290 family the cells are able to rescue the defect and continue to 
proliferate (278). These miRNAs were shown to suppress several important regulators of the 
G1/S transition. This shows the importance of miRNA regulation in at this specific cell cycle 
phase.  
O'Donnell's group showed in 2005 that E2F is targeted by two miRNAs, miR-17-5p and miR-
20a (279). C-Myc and E2F are both targeting each other’s promoter (280,281) and miR-17-5p 
and miR-20a provides a mechanism that control this positive feedback loop and the 
expression of both c-Myc and E2F.  
Other miRNAs are also shown to regulate E2F. E2F1 is a validated target for miR-149, miR-
330 and miR-331-3p (282-284) and similar E2F3 is targeted by miR-125b, miR-210 and miR-
195 (285-287). In most of these studies, de-regulation of these miRNAs is associated with 
altered cell growth or tumorigenesis.  
The retinoblastoma protein (Rb) is tumor suppressor protein that is functionally connected 
with E2F. Rb binds and inhibits E2F and thereby prevents the cell from entering enter S phase 
(288). When Rb is phosphorylated by CDKs, E2F is released and the cell is able to progress 
from G1  to S phase. Although Rb seems to be mainly regulated by phosphorylation, several 
reports show that miRNAs are functionally regulating Rb family members. The miRNA 
cluster miR-17-92 targets and down-regulates Rb2/p130, a member of the Retinoblastoma 
family, thereby promoting differentiation in adipocyte tissue (289). The miR-290 cluster 
targets Rbl2, thereby controlling DNA methylation through the interaction between Rbl2 and 
multiple DNA methyltransferases (290). Rb itself is also targeted by miR-106a (291).  
MicroRNAs are regulating several genes encoding cyclin-dependent kinases inhibitors 
(CKIs). CKIs are divided into two families: INK4 and Cip/Kip (292). Some important 
members of the INK4 family are p15, p16, p18, and p19 whose function is to inhibit the 
activity of CDK4 and CDK6 (reviewed in (293)) (Fig 7). The Cip/Kip comprises p21, p27, 
and p57 and this family regulates many other CDK proteins (293). MiR-24 and miR-31 was 
shown to control proliferation by regulating the CDK4/6 specific inhibitor p16INK4a (294) and 
p21Cip1 is targeted by several miRNAs, including miRNAs in the miR-17-92 family and miR-
106b (295,296). One of the most studied miRNAs in the cell cycle, miR-221/222, together 
with miR-181, control the expression of two of the most important cell cycle inhibitors 
p27Kip1 and p57Kip2 (297,298) and reviewed in (299).  
=C
4.8.3. MicroRNAs and mitosis 
Although most miRNA regulation seems to take place at G1 and S phase of the cell cycle, 
some reports show that miRNAs are also active in later cell-cycle phases. CDK1 together with 
cyclin A and cyclin B is the master regulator in mitosis and its activation is dependent on de-
phosphorylation (reviewed in (300)). The microRNAs miR-125b, miR-24 and let-7 regulates 
cyclin A and cyclin B, however most of these studies focuses on the role of these cyclins in 
G1 and S phase (285,301,302). Furthermore, miR-195, miR-516-3p, miR-128a and miR-381 
are all validated to regulate the CDK1 inhibitor Wee1, one of the important G2/M regulators 
(303-305).    
Taken together, given the large network of proteins involved in cell cycle regulation it is not 
unexpected that miRNAs contribute in the regulation. Focusing on the main cell cycle 
regulators we have seen that several miRNAs are targeting these genes, indicating that 
miRNAs are important molecules in cell division. 
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Paper I: 
- Identify cell cycle regulated transcripts in the human non-tumorigenic, keratinocytic 
cell line HaCaT. 
Paper II: 
- Provide an updated list of human DNA repair and chromatin remodeling genes. 
- Characterize cell cycle regulated DNA repair pathways and chromatin remodeling 
genes. 
- Make a database of cell cycle regulated human DNA repair and chromatin remodeling 
genes. 
Paper III: 
- Investigate how lost Ago2 affects miRNA and mRNA expression in normal cycling 
and serum stimulated mouse embryonic fibroblasts. 
Paper IV: 
- Investigate how lost Ago2 affects miRNA and isomiR expression in mouse embryonic 
fibroblasts. 
- Identify sequence and structure characteristics that affect miRNA sorting in 
mammalian cells by analyzing Ago2 knock-out cells and available Ago IP small RNA 
sequencing data sets. 
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Paper I - Transcription profiling during the cell cycle shows that a subset of Polycomb-
targeted genes is upregulated during DNA replication. 
Previous studies performing gene expression analysis on synchronized cells have shown that a 
large subset of genes are periodically expressed in the human cell cycle (306-308), as well as 
in other organisms (309-311). One study showed that there is significant overlap between cell 
cycle regulated genes in cancer and normal cells (306) and that some genes are unique for 
each cell type. In Paper I, we used whole transcriptome microarrays on double-thymidine 
and nocadazole synchronized cells to identify periodically expressed genes in human HaCaT 
keratinocytes as well as the human cervical cancer HeLa cells. We identified 1249 genes as 
cell cycle regulated which we divide in three groups. One group includes genes with 
housekeeping functions, characterized by high baseline expression and CpG-rich promoters 
carrying the histone H3 lysine 4 tri-methylation (H3K4me3) chromatin mark, associated with 
active transcription. The second category included genes specific for HaCaT cells, which 
were mostly unique compared to other cell types. The third category included genes carrying 
the histone H3 lysine 27 tri-methylation (H3K27me3) chromatin mark, associated with 
Polycomb silenced genes (312). Surprisingly, we identified a subset of the Polycomb-targeted 
genes to be up-regulated during G1/S or S phase. This finding was confirmed in other cell 
lines and suggests that DNA replication offers a possibility for H3K27me3 silenced genes to 
be expressed by making the chromatin accessible for transcription factors.  
Paper II - Cell cycle regulation of human DNA repair and chromatin remodeling genes. 
To facilitate repair of damaged DNA, integration between DNA repair proteins and chromatin 
remodeling proteins is needed (66,101,111). Several DNA repair genes are cell cycle 
regulated (313,314), and proper regulation of these genes is needed to prevent incorrect 
transmission of genetic information (315). In paper II, we combined published and un-
published cell cycle data sets to get an overview of cell cycle regulated DNA repair and 
chromatin remodeling genes. Each pathway is analyzed separately and we show that long 
patch base excision repair (BER) is enriched for S phase genes; whereas short patch BER uses 
genes expressed in all cell cycle phases. Furthermore, we show that MMR genes, Fanconi 
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anemia genes and homologous recombination genes are up-regulated during S phase. Other 
DNA repair pathways show less consistent cell cycle regulation. Several chromatin 
remodeling genes were found to be up-regulation during G1/S- and S phase, including 
chromatin assembly factor 1 (CAF-1) major subunits CHAF1A and CHAF1B; the putative 
helicases HELLS and ATAD2, both involved in E2F activation and DNA double strand break 
repair, and RAD54L and RAD54B also involved in  DNA double strand break repair. Finally, 
paper II provides an update of DNA repair and chromatin remodeling genes and shares the 
information through a novel Internet page where the expression profile for the genes can be 
viewed individually.  
Paper III - Argonaute2 affects Hox gene expression and the late growth response in 
mouse embryonic fibroblasts. 
Argonaute2 (Ago2) is the central protein in miRNA regulation. In contrast to the other Ago 
proteins, Ago2 possesses endonuclease activity, enabling cleavage of highly complementary 
mRNA targets (316) and miRNA duplexes (317). In paper III, we investigated time 
dependent changes in global gene expression between serum-stimulated Ago2 knock out 
(KO) and wild type (WT) MEF cells. We observed significant changes in the development-
related Hox genes, a majority of which were up-regulated in Ago2 KO, suggesting that Ago2 
plays an essential role in regulating this cluster of genes. In detail, we observed repression of 
posterior Hox genes in Ago2 KO whereas anterior Hox genes are highly up-regulated. This 
suggests that WT cells activate a posterior Hox gene program, which is lost when Ago2 is 
removed from the cells, leading to activation of the anterior Hox program. Furthermore, we 
found that Ago2 KO cells recover more slowly from the serum starvation than the WT cells, 
probably as a result of differences in the activation of transcriptional programs between the 
two cell types.  
Paper IV - Deep sequencing of Ago2 knock-out cells reveals distinct sequence and 
structure features associated with miRNA sorting. 
While much is known about the processing cascade and targeting mechanisms of miRNAs, a 
good model for how miRNAs are loaded into the different Ago protein remains to be 
described. In paper IV we analyzed miRNA sequences from Ago2 KO and WT cells to 
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determine the effects of Ago2 on the global miRNA population, and to identify sorting 
features for miRNAs. We identified several sequence and structure features that could 
influence miRNA sorting. Analysis of isomiR length showed that long isomiRs were up-
regulated in Ago2 KO whereas short isomiRs were down-regulated in Ago2 KO. Moreover, 
we observed significant differences in base-pairing between Ago2 KO and WT. Specifically; 
base-pairing at the 5’ nucleotide and in the central region of the miRNA duplex were 
associated with up-regulation in Ago2 KO cells. We also found that miRNAs down-regulated 
in Ago2 KO have less stable 5’ ends. When analyzing a panel of Ago IP data sets, we 
observed similar base-pairing trends as in the Ago2 KO study. Here, base-pairing at the 5’ 
nucleotide were associated with miRNAs down-regulated in Ago2 IP, which confirms the 
finding in Ago2 KO. The results indicate that Ago2 is more sensitive to base-pairing at the 5’ 
nucleotide than the other Ago proteins, and that Ago2 prefers an unpaired 5’ nucleotide. 
Finally, we extended the analysis of Ago2 KO cells with a meta-analysis of six datasets of 
small RNAs extracted from protein immunoprecipitation (IP) of the different Ago proteins. 
The meta-analysis confirmed the major features identified in Ago2 KO, and identified several 
additional Ago2 specific miRNA features. Together, the results from paper IV indicate that 
miRNAs associated with Ago2 have distinct structure and sequence specifics, involving base-
paring, length and thermodynamics, which all may serve as sorting features for Ago2. 
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Coordinated regulation of gene expression is fundamental for the cell to function properly and 
to prevent disease. Protein production is influenced by the rate of mRNA transcription from a 
given locus, which again is regulated by transcription factors’ access to the chromatin. The 
mRNAs are subject to regulation by several mechanism including splicing, capping and 
polyadenylation, which controls stability of the mRNAs. The stability is again challenged by 
miRNAs that can bind and degrade mRNAs. Several studies have tried to integrate the 
different regulatory processes to understand when and to what degree they play a role in the 
cell (318-322), and there are dedicated journals covering this field (323,324). In the current 
thesis we have used high throughput sequence data to analyze changes in gene expression and 
we have demonstrated how time-series experiments can be used to identify changes that only 
become visible over time. The following sections discuss strengths and weaknesses of the 
methods we have used in the different studies as well as other available methods.   
7.1. Does mRNA abundance mirror that of proteins? 
In paper I and II we utilize high throughput gene expression arrays to explain the activity in 
biological pathways. In paper II we show that several DNA repair pathways are associated 
with S phase regulated genes, including long patch base excision repair, DNA mismatch 
repair, Fanconi anemia and homologous recombination, and we discuss these observations in 
the perspective of the role for these pathways in repairing lesions that occur during S phase. 
Likewise, we suggest that pathways that are not enriched in a particular cell cycle phase 
repairs lesion independently of cell cycle phases. In paper I and II we assume that transcript 
abundance is a major determinant of protein abundance. However, this may not always be the 
case. 
The question of how well changes in mRNA concentration actually reflect the output and 
activities of the corresponding protein has previously been addressed. Recent advances in 
technology have made it possible to measure activities at basically every level of regulation, 
including DNA methylation (microarrays or sequencing), transcription (microarrays or RNA-
Seq), translation (ribosomal profiling), protein and protein modification (mass spectrometry). 
However, some of these technologies have previously been associated with low sensitivity, 
especially those measuring protein abundance (325). New methods have increased the 
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sensitivity; however, some challenges still remain. For instance, stable isotope labeling by 
amino acids in cell culture (SILAC), which measures peptide abundance using mass 
spectrometry, are only able to measure a subset of the expressed proteins. In case of detecting 
cell cycle regulated proteins, if SILAC is only able to detect ~2000 proteins (326) and more 
that 1000 genes are predicted to be cell cycle regulated (306,313,314), many proteins will be 
missed using this approach However, because different methods are measuring different 
molecules, it does not always make sense to compare sensitivity without considering the 
molecules itself.  
Studies from bacteria and mammalian cells have reported correlations between protein and 
mRNA with a Pearson correlation coefficient of ~0.40, thus saying that about 40% of the 
variation in protein abundance can be explained by variation in mRNA expression. This 
implies that ~60% of protein variation is due to differences in translation efficiency between 
mRNAs, post-transcriptional modifications or noise in the measurements (reviewed in (327) 
and original papers in (328-330)). These studies do not consider differences in the degradation 
rate between mRNA and protein, and it is known that mRNAs are produced at a much slower 
rate than proteins in addition to being more prone to degradation (reviewed in (327)). RNAs 
and metabolites are very stable and have a high protein-per-mRNA ratio, whereas mRNAs 
from transcription factors, signaling genes, chromatin modifying enzymes and genes with 
cell-cycle-specific functions are generally more unstable (328). These are genes known to be 
highly regulated, and higher fluctuations in mRNA levels are expected as a response to 
stimulus (328).  
Other studies have tried to explain the remaining 60% of protein variation using mammalian 
cells (328,331). The conclusion from these studies was that translation efficiency and protein 
degradation are the main contributing factors for the observed variation, whereas 
experimental noise was almost negligible.   
Although the correlation between mRNA levels and protein levels is not perfect, measuring 
the mRNA levels remains a good approximation for the abundance of a protein (332). In a 
biological system where the protein is either present or non-present at a given time, levels of 
mRNAs will most likely be the determining factor for protein abundance, which is regulated 
through transcriptional bursts (327). Such on and off states of mRNA levels have been 
described in mammalian and bacterial cells. Transcription factors are thought to be the main 
player to control the switch in protein abundance, and other regulatory mechanisms like 
miRNAs and post-transcriptional modifications work as fine tuners of (333,334). 
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In summary, measuring mRNA levels should give a good estimation of protein activity in 
closed biological systems where high fluctuations are expected, as for example synchronized 
cell cultures which are used in the current papers. However, to understand all the changes 
taking place in the cell, these methods have to be supplemented using matched data sets 
where multiple levels of regulation are considered in the same samples. In paper II we added 
a translational data set to the analysis. However, in this case more time points and cell lines 
need to be included to get a better picture of the translational changes in the cell cycle.  
7.2. Use of cell synchronization to study cell cycle regulation 
The most common way to measure changes in the cell cycle is to use synchronized cell 
cultures and harvest cells at given time points after the cells have been released from the 
synchronization block (335).  Several such methods have been developed that block cells at 
mitosis (nocodazole and mitotic shake-off), G0 phase (serum starvation) or at the G1/S 
transition (double thymidine). Even if these are well-established methods, it has been debated 
whether they are suited to study cell cycle related events (336-341). A controversy between 
Stephen Cooper and Paul T. Spellmann highlighted problems associated with these methods, 
and Cooper proposed that whole-culture methods alter the size and genome composition of 
cell cultures in a way that deviates from the normal cell cycle. Spellmann and Sherlock 
replied to the critique by listing five arguments proposing that whole-culture synchronization 
methods are indeed suitable to study cell cycle gene expression (340,341): (i) whole-culture 
synchronized cells are dividing normally; (ii) The overlap between orthologous genes 
identified by these methods are good across organisms;  (iii) the genes identified as cell cycle 
regulated frequently regulate cell cycle processes; (iv) studies from whole- and selection-
synchronized cultures show good overlap in terms of significant cell cycle genes; (v) 
individual cells display the same significant cell cycle genes. 
One of the main challenges with cell synchronization is the tendency for cells to loose 
synchronization over time. As seen from the flow cytometry charts in the Paper I and, II, a 
substantial fraction of cells have delayed entry into the second cell cycle. Because of this, cell 
cycle gene expression cannot be monitored for a consecutive number of cell cycles, which 
would be favorable to eliminate technical noise from the synchronization procedure. 
Therefore, a combination of synchronization methods are often used which block cells at 
different cell cycle phases (reviewed in (342)).  
>A
When cells are released from the synchronization block, new cell culture medium is added to 
the cells. This results in rapid activation of growth related genes and a cascade of serum-
dependent gene expression is often observed (343). These genes can sometimes be incorrectly 
annotated as cell cycle regulated. We considered these effects by constructing two different 
models to monitor cell cycle gene expression. The cell cycle model identifies genes having 
oscillating expression profiles reminiscent of a sine/cosine curve. The serum-model identifies 
genes having transient expression changes. Transient expression changes are roughly divided 
into immediate, early, intermediate and late changes (described in (343)). Using two models, 
we were in paper I and II able to separate technical changes from biological changes and 
thereby reduce the number of false positive cell cycle genes.   
7.3. Using time-series data to detect biological changes 
Most biological processes are dynamic, meaning that they change over time. A common 
theme in the present thesis is the use of time-series data to identify dynamic changes in the 
cell. The common approach has been to use gene expression data, from either microarrays or 
high-throughput sequencing. In this way, changes can be monitored in a complete set of active 
genes. Systems that easily produce large populations of synchronized cells are ideal for this 
type of studies.  
When designing a cell cycle synchronization experiment, one important question is how 
frequent the sampling should be to cover most of the changes. When measuring oscillating 
processes like the cell cycle, the sampling should be uniform and cover all cell cycle phases 
(reviewed in (344)). If the synchronization method involves medium replacement, which is 
the case for most synchronization methods, more sampling should be performed at early time 
points to control for early transient changes that may resemble cell cycle changes. In paper I 
and II, we have considered this in two ways. First by constructing two different PLS models, 
one model that captures transient serum related changes and one model that captures cell 
cycle related changes resembling a sine/cosine type of expression. Secondly, we increased the 
sampling rates for early time points. Separating between cell cycle and serum dependent 
expression will help identify changes that are directly related to the cell cycle but also changes 
that are related to proliferation.  
Another consideration in time-series experiments is whether to include more replicates or 
more time points in the experimental setup. More replicates will increase statistical power 
which makes it easier to identify significant genes at the given time points. Adding more time 
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points will exclude more false positive cell cycle genes since genes for which the expression 
spikes at specific time points are removed (344). In paper I and II, adding more time points 
may have resulted in more significant transcripts.  Another advantage of dense sampling rates 
is the possibility to identify causal relationships between genes. Amit et al. have demonstrated 
this when they characterized feedback regulation between transcription factors in EGF 
stimulated HeLa cells (343). Using 20 minute sampling rates they constructed a kinetic profile 
of growth factor-induced transcription, demonstrating that transcription takes place in clearly 
defined waves. We used a similar approach in paper III when analyzing growth responses in 
cells lacking Ago2. Here we showed that Ago2 knock out affects late serum responses while 
having limited effect on early biological functions. In paper II, we used the information on 
cell cycle regulated genes obtained from paper I in addition to public available data sets to 
map different DNA repair pathways to the cell cycle. Here we showed that genes related to 
the same DNA repair pathway are often expressed in the same cell cycle phase, indicating that 
there is a link between expression and function.  
In summary, throughout the thesis we have shown how time-series experiments can be used to 
identify changes in dynamic systems and how transcriptome analysis elucidates interactions 
between genes in biological systems.  
7.4. Challenges with immunoprecipitation and knock-out 
experiments 
In paper I and paper IV we have analyzed DNA and RNA pulled out from the cell using 
specific antibodies. Such experiments rely strongly on the specificity of the antibodies used. 
High quality antibodies are specific to the target protein. Antibodies are classified into 
monoclonal and polyclonal, depending on the number of epitopes they recognize. Monoclonal 
antibodies recognize only one epitope on the target protein, whereas polyclonal antibodies 
recognize multiple epitopes. Because monoclonal antibodies are more specific to the target 
epitope, they usually have less background compared to polyclonal antibodies. When working 
on similar proteins, as for example protein homologs, monoclonal antibodies are generally 
preferred. High antibody specificity is particularly relevant for the Argonaute homologs 
analyzed in paper IV. The specificity of Argonaute antibodies have been discussed by Siomi 
et al. (345) and monoclonal antibodies against the human and mouse Argonaute2 protein are 
successfully developed (346,347), as well as for human Ago1 (348), human Ago3 (199) and 
human Ago4 (206). The availability of these antibodies makes it possible to identify small 
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RNAs specific for each Ago protein. In paper IV we used available Ago IP data sets to look 
for miRNA sorting in mammalian cells. Most of the studies included in the meta-analysis in 
paper IV fail to observe differences in miRNA association between the Ago proteins; 
however, they report to have used specific antibodies. Given that the antibodies are specific, 
one reason why the studies fail to detect Ago specific miRNAs could be lack of replicates in 
the IP experiment, making it difficult to perform statistical analysis on the data. When 
replicates are limited, only prominent differences will be detected.  
Another way of detecting small RNAs associated with a particular Ago protein is to make Ago 
deficient cells. In this way, problems with unspecific antibody binding are eliminated. In 
paper IV, we have sequenced small RNAs from Ago2 deficient cells to investigate changes in 
the population of miRNAs. By looking at which miRNAs are affected by the KO, we may be 
able to detect potential miRNA preferences for Ago2. However, we need to be aware that 
Ago2 may have an effect on transcription in general; meaning that when Ago2 is removed 
from the cell, the transcription of miRNA-coding genes may change. One way to adjust for 
this is by looking at clustered miRNAs. These effects are discussed in more detail in paper 
IV.  
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This section discusses the importance of the finding is the papers, in addition to suggestions 
on new experiments to support and get a deeper understanding of the findings. Some future 
perspectives are included in the papers and will therefore not be included here.   
In paper I we show that a subset of Polycomb associated genes is up-regulated during DNA 
replication, thus providing a model for replication dependent transcription of these genes. 
Several studies have suggested that non-coding RNAs may play an important role in 
maintaining Polycomb associated chromatin marks (349-351). Little is known about the role 
of non-coding RNAs in cell cycle regulation, especially in the context of Polycomb mediated 
regulation. Furthermore, the exact mechanism of how the cell maintains the correct chromatin 
marks after DNA replication is not known. We speculate that non-coding RNAs may have a 
role in this regulation. Experiments are planned to investigate the expression of non-coding 
RNAs as well as Polycomb associated loci during the cell cycle. Specifically, we will perform 
IP of the two histone marks H3K27me3 and H3K4me3 at multiple time points during the cell 
cycle in HaCaT cells. The IP samples will be matched with RNA-Seq samples to detect non-
coding RNAs at the same time points. 
In paper II we investigated the role of DNA repair genes during the cell cycle and show that 
several DNA repair pathways are associated with specific cell cycle phases. These analyses 
were based on gene expression data sets, in addition to one data set on ribosomal profiling. 
Utilizing current methods measuring protein abundance and translation rates would be 
valuable to support the findings in paper II, and give a more complete picture of the network 
of DNA repair pathways in the cell cycle.  
In paper III and IV we investigated the role of Argonaute protein 2 (Ago2) and show that 
knocking out Ago2 from mouse embryonic fibroblasts (MEFs) is associated with major 
changes in mRNA and miRNA levels. In paper IV we observed clear structure and sequence 
differences between up-and down-regulated miRNAs in Ago2 KO. To test if these structure 
and sequence features are indeed preferred by Ago2, transfecting RNA constructs harboring 
these features into Ago2 wild type cells followed by Ago2 IP and deep sequencing, will 
highlight such preferences. Finally, expressing the full-length Ago2 protein in MEF Ago2 
knock-out cells will tell if the time dependent changes we observed in paper III were Ago2 
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specific. Similar, expressing a catalytic mutant of Ago2 would test if the changes in Hox gene 
expression were due to Ago2 cleavage, as proposed in paper III.  
Recent publications have shown that Ago2 has a specific role in recruiting repair factors to 
DSBs, guided by a class of small RNAs termed DSB-induced small RNAs (diRNAs) 
produced in the vicinity of these sites (9,352). Other Ago proteins fail to do so, indicating that 
the recruitment is dependent on the catalytic activity of Ago2 (220,353). These findings show 
that the role of Ago2 goes beyond miRNA mediated gene repression, and small RNAs seem 
to have a conserved role in DSB repair. Further studies should be conducted to show how and 
where diRNAs are transcribed in the genome and why they are specific to Ago2.  
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ABSTRACT
Genome-wide gene expression analyses of the
human somatic cell cycle have indicated that the
set of cycling genes differ between primary and
cancer cells. By identifying genes that have cell
cycle dependent expression in HaCaT human kera-
tinocytes and comparing these with previously
identified cell cycle genes, we have identified three
distinct groups of cell cycle genes. First, house-
keeping genes enriched for known cell cycle func-
tions; second, cell type-specific genes enriched for
HaCaT-specific functions; and third, Polycomb-
regulated genes. These Polycomb-regulated genes
are specifically upregulated during DNA replication,
and consistent with being epigenetically silenced
in other cell cycle phases, these genes have lower
expression than other cell cycle genes. We also
find similar patterns in foreskin fibroblasts,
indicating that replication-dependent expression of
Polycomb-silenced genes is a prevalent but unrec-
ognized regulatory mechanism.
INTRODUCTION
Genome-wide studies of gene expression throughout the
cell division cycle have revealed several genes that are dif-
ferentially expressed (1–9), but have also indicated that the
set of cycling genes differs between primary and cancer
cells (3). Primary cells are, however, inherently difﬁcult
to synchronize, for example, only 40–50% of foreskin
ﬁbroblast cells in culture can be synchronized by serum
starvation or double thymidine block (3). Although
sophisticated statistics may partially overcome lack of syn-
chronization (3), a large population of asynchronous or
arrested cells results in high background gene expression
noise. Consequently, more cycling genes can be detected in
a highly synchronous culture than in a culture where at
most 50% of the cells are synchronized. Moreover, as the
only human cell line—in addition to primary ﬁbroblasts
(1,3,4)—proﬁled for cell cycle expression so far is the
cervical cancer cell line HeLa (2,5), it is unclear to what
extent cell type-speciﬁc factors affect reported differences
in cycling genes.
We have used the human keratinocyte cell line HaCaT
to address this question. Speciﬁcally, by measuring the
gene expression proﬁles of double thymidine synchronized
HaCaT cells, we identiﬁed three major groups of cycling
genes. First, a set of genes with housekeeping characteris-
tics, strong enrichment for known cell cycle functions and
overlap with previously identiﬁed cell cycle genes. Second,
a set of genes with cell type-speciﬁc characteristics, enrich-
ment for HaCaT-speciﬁc functions and poor overlap with
previously identiﬁed cell cycle genes. Third, a set of genes
that has the mark for Polycomb silencing: histone H3
lysine 27 tri-methylation (H3K27me3). We show that
this third set of genes is expressed in a replication-
dependent manner, as the genes are upregulated during
S phase in a pattern related to DNA replication timing.
Consistent with being epigenetically silenced in other cell
cycle phases, these genes are generally lower expressed
than are other cell cycle expressed genes. We also ﬁnd
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similar patterns in foreskin ﬁbroblasts synchronized by
serum starvation, indicating that replication-dependent
expression of Polycomb-silenced genes is a prevalent but
unrecognized regulatory mechanism.
MATERIALS AND METHODS
HaCaT cell culture and synchronization
HaCaT cells were plated at 10% conﬂuence (1 106 cells)
in 150-mm tissue culture dishes in Dulbecco’s modiﬁed
Eagle’s medium (DMEM) with 10% fetal bovine serum
(FBS). Cells were arrested in the interphase G1/S by
double thymidine block; brieﬂy, cells were treated with
2mM of thymidine for 18 h, released from the arrest for
10 h and arrested a second time with 2mM of thymidine
for additional 18 h. After treatment, media was replaced,
and cells were collected at 3-h intervals for up to 33 h,
covering approximately two cell cycles. Synchrony was
monitored by ﬂow cytometry analysis of propidium
iodide-stained cells and by cell counting. Quantiﬁcation
of cells in each phase was done with the MultiCycle
DNA cell cycle analysis software (Phoenix Flow Systems
Inc., San Diego, CA, USA) combined with the cell
counting results.
HeLa cell culture and synchronization
Adherent HeLa cells were plated in 150-mm culture dishes
in DMEM with 10% of FBS, 2mM of glutamine,
0.1mg/ml of gentamicin and 1.25mg/ml of fungizone.
Cells at 60–70% conﬂuence were arrested in the G2/M
transition with 100 ng/ml of nocodazole for 17 h. The
mitotic cells were then collected by manual shake-off,
washed twice and re-plated in fresh DMEM to progress
through the cell cycle. Cells were harvested from culture
dishes by trypsinization every 30min for the ﬁrst 2 h and
then every 3 h from 3 to 24 h after release. Phosphate-
buffered saline containing 3% of FBS was added to in-
activate the trypsin.
HeLa cells were pelleted and resuspended in 100 ml of
RNAlater (Applied Biosystems/Ambion, Austin, TX,
USA). All pellets were kept at 4C overnight and were
stored at 80C before use. Veriﬁcation of the cell cycle
stage was determined by analysing the DNA content of
propidium iodide-stained cells by a BD FACSAria (BD
Biosciences, San Jose, CA, USA) ﬂow cytometer.
Quantiﬁcation of cells in each phase was done with
FlowJo (Tree Star Inc., OR, USA).
cRNA synthesis and microarray hybridization—HaCaT
Total RNA was extracted using the High Pure RNA
Isolation Kit (Roche Applied Science, Indianapolis, IN,
USA) and the manufacturer’s protocol. RNA from
synchronous cells was reverse transcribed into cDNA
(cDNA synthesis Kit, Invitrogen, Carlsbad, CA, USA),
which was used as a template for the RNA polymerase
Enzo (Affymetrix, Santa Clara, CA, USA) to synthesize
dUTP–dCTP biotinylated cRNA. The labelled cRNA
was hybridized to Affymetrix oligonucleotide arrays
(HG-U133 Set) under conditions speciﬁed by the
manufacturer.
Microarray analyses—HeLa
Total RNA was prepared using the mirVana miRNA
Isolation Kit (Ambion) according to the manufacturer’s
protocol. The integrity and stability of RNA samples were
assessed by Agilent 2100 Bioanalyzer (Agilent Techno-
logies, Santa Clara, CA, USA). We used the Illumina
TotalPrep RNA ampliﬁcation Kit (Ambion) to amplify
RNA for hybridization on Illumina BeadChips. Total
RNA from each sample was used to synthesize ﬁrst
strand cDNA by reverse transcription. After the second
strand cDNA synthesis and cDNA puriﬁcation steps, the
in vitro transcription to synthesize cRNA was prepared
overnight for 12 h. The gene expression proﬁles were
measured using Illumina HumanHT-12 v3 Expression
BeadChip (Illumina, San Diego, CA, USA).
Identiﬁcation of periodically expressed genes—statistical
analysis
Normalization across arrays was performed by robust
multi-array average (RMA) from the Bioconductor
package affy (10). As there are no probes speciﬁc for
splice variants in the arrays used, for probes that
hybridized with mRNAs corresponding to the same gene,
only the probe having the highest variation was used for
further analyses. The normalized data were then used to
identify genes that showed cyclic behaviour. Genes that
matched a cell cycle proﬁle were identiﬁed using partial
least squares (PLS) regression. Speciﬁcally, the gene ex-
pression matrix was regressed on to a sine and cosine
function with periods equal to the estimated duration of
the cell cycle. False discovery rates were computed using a
modiﬁed Hotelling’s T-square statistic and resampling.
Resampling (n=1000) was done by assigning phase
angles randomly to the time-steps, thus preserving the cor-
relation within replicates of the same time-steps.
Assigning cell cycle phases
Assignment of cell cycle phases used the following
protocol. First, each gene in the PLS model was
assigned a phase angle by computing the arctangent of
the gene’s ﬁrst and second principle component. Second,
we used a list of genes previously published to be predom-
inantly expressed in G1/S, S, G2, G2/M and M/G1 phase
[(2): Table 2 and the four M/G1 associated genes from
Figure 2] and identiﬁed which of these genes were signiﬁ-
cant (q< 0.05) in our PLS model (Supplementary Figure
S3A). Third, for each set of signiﬁcant G1/S, S, G2, G2/M
and M/G1 phase genes, we computed the set’s average
phase angle and the corresponding standard deviation
and used these values as parameters in a normal distribu-
tion to construct a phase angle probability density
function for each of the ﬁve cell cycle phases
(Supplementary Figure S3A). Fourth, we used these prob-
ability density functions to assign the most probable phase
IDs to each of the signiﬁcant (q< 0.05) genes in the PLS
model. Fifth, if necessary, the standard deviation param-
eters in the phase angle probability density functions were
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increased to ensure that the phase assignments had the
same order as the average phase angles for the ﬁve
groups. Speciﬁcally, if any out of order phase assignments
were detected, the lowest of the ﬁve standard deviations
was increased by 25%, and the phase assignments were
redone. This process was repeated until all phase assign-
ments were in the order deﬁned by the averages.
Promoter CpG analyses
Gene annotations were downloaded from the refGene
table in the University of California, Santa Cruz
(UCSC) Genome Browser database (human genome
assembly version hg18) (11). Promoter regions were
deﬁned as the 1000 nt upstream of annotated transcription
start sites. Overlapping regions corresponding to genes
with multiple transcripts having identical or alternative
start sites were merged into one region to create a
non-redundant set of promoter regions. Based on this
non-redundant set, CpG ratios and CpG promoter
classes were calculated and assigned as previously
described (12).
Promoter histone analyses
Processed peak data from chromatin immunoprecipitation
sequencing (ChIP-seq) experiments of H3K4me3 and
H3K27me3 in seven cell lines (GM12878, HUVEC,
K562, NHEK, H1-hESC, HMEC and NHLF) were
downloaded from UCSC (hg18) (13,14). Non-redundant
promoter regions that contained overlapping H3K4me3
and H3K27me3 peaks in all seven cell lines were classiﬁed
as H3K4me3 and H3K27me3 enriched, respectively;
promoter regions that contained both marks in all seven
cell lines were classiﬁed as bivalent; and promoter regions
that did not contain any of the marks or only contained
the marks in some of the cell lines were classiﬁed as having
no or inconsistent marks.
Processed peak data from ChIP-seq experiments of
H3K4me3 and H3K27me3 in HeLa and normal adult
dermal ﬁbroblasts (NHDF-Ad) were downloaded from
UCSC (hg19; Broad Histone track) and remapped to
hg18 by the UCSC liftOver tool.
HaCaT ChIP-seq
ChIP, library preparation and sequencing were done as
described in the Supplementary Methods. The resulting
input chromatin and H3K4me3 and H3K27me3 IP
libraries contained 64 million (M), 42M and 52M
sequence reads, respectively. We used cutadapt (15) to
trim adapter sequences, bowtie (16) to align sequence
reads from the human genome (version hg18) and dis-
carded all reads that aligned to more than one genomic
location. The 50M, 32M and 39M aligned reads for
the input, H3K4me3 and H3K27me3 libraries, respect-
ively, were processed by SICER (17) to identify genomic
regions that were signiﬁcantly enriched for H3K4me3 and
H3K27me3 in HaCaT (SICER used the input chromatin
library as control to identify signiﬁcant regions; see
Supplementary Dataset S3 and S4).
Gene ontology and Kyoto Encyclopedia of Genes and
Genomes analyses
Gene ontology (GO) term and Kyoto Encyclopedia of
Genes and Genomes (KEGG) pathway enrichment was
assessed by GOstats (18). For GO terms, the test was con-
ditioned on the structure of the GO graph.
Data access
The microarray data from this publication have been
submitted to the ArrayExpress database (http://www.ebi.
ac.uk/arrayexpress/) and were assigned the identiﬁers
E-MTAB-454 (HaCaT) and E-TABM-1152 (HeLa).
HaCaT ChIP-seq data are available from http://tang.
medisin.ntnu.no/palsat/HaCaT-ChIP.tgz; bed-ﬁles with
signiﬁcant H3K4me3 and H3K27me3 regions are avail-
able as Supplementary Dataset S3 and S4.
RESULTS
Partial least squares regression identiﬁes cell
cycle-regulated transcripts
To overcome the problem of low synchronization of
primary cells and to investigate potential cell type-related
differences in cycling genes, we turned to the human kera-
tinocyte cell line HaCaT—a non-tumorigenic, spontan-
eously immortalized cell line that exhibits apparently
normal differentiation (19). Using a double thymidine
block to arrest and, subsequently, release HaCaT cells at
the G1/S boundary resulted in 90% of the cells re-
entering the cell cycle and continuing as a uniform
cohort through the cell cycle (Supplementary Figure S1).
Based on the DNA content proﬁle, we estimated the cell
cycle duration to be 20 h. Although the cells gradually
lost synchrony, such that 70% instead of 90% of the cells
were synchronously entering the second S phase, the
results were reproducible across three independent experi-
ments. We, therefore, considered synchronized HaCaT
cells a good starting point for gene expression analyses.
We were primarily interested in genes that showed con-
sistent cyclic expression with a period equal to the
estimated cell cycle duration of 20 h. We, therefore, used
PLS (20) to identify genes that followed a sine or cosine
pattern with a period of 20 h. Conceptually, this PLS
analysis projects the time proﬁle for all genes onto a
plane described by the sine and cosine of the cell cycle.
As a result, genes that are periodically expressed with high
amplitude will be far from the origin, whereas genes that
vary little or randomly will be close to the origin.
Moreover, the phase angle of the cyclic variation will de-
termine the direction from the origin such that genes that
have the same temporal expression patterns will lie in the
same direction from the origin on the plane.
By proﬁling RNA isolated from the synchronized cells
at 3 h intervals for 33 h, and combining PLS analyses with
resampling to compute false discovery rates (21), we
identiﬁed 1249 Entrez genes that had signiﬁcant periodic
expression patterns during the HaCaT cell cycle (Figure 1,
Supplementary Dataset S1). The synchronization experi-
ments’ trajectory through the PLS cell cycle plane
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conﬁrmed that the three replicates gave similar and repro-
ducible results (Figure 1B). The trajectory also indicated
the cells’ gradual loss of synchrony, as the samples were
gradually approaching the origin—especially at later time
points.
To further analyse the cell cycle genes, we used existing
annotations (2) to subdivide the genes into ﬁve main
groups that represented phases G1/S, S, G2, G2/M and
M/G1 of the cell cycle (Figure 1; see ‘Materials and
Methods’ section). The assigned phases showed good cor-
respondence with previously published phases
(Supplementary Table S1); the genes missing from our
list had expression patterns that were either inconsistent
between replicates, not cyclic, or consistently expressed in
the ﬁrst cell cycle only (Supplementary Figures S2–S4;
Supplementary Discussion S1). We, therefore, concluded
that our PLS model could robustly identify genes that
showed consistent and reproducible cyclic expression
patterns within the synchronized HaCaT cells.
HaCaT cell cycle genes include both generally active
housekeeping and keratinocyte-speciﬁc genes
Having established a set of genes with cell cycle-dependent
expression, we set out to characterize these genes further.
As cell cycle control is a central housekeeping function, we
expected our set of genes to be enriched for high-CpG
(HCG) promoters—a hallmark of developmentally
regulated genes and housekeeping genes (12,22). We also
expected the cell cycle genes to be enriched for histone H3
lysine 4 tri-methylation (H3K4me3) within their promoters,
as this epigenetic mark is associated with actively
transcribed genes (23,24). Indeed, although the complete
set of genes followed a bimodal distribution of HCG and
low-CpG (LCG) promoters (12,22), the distribution for the
cell cycle genes was shifted, such that a larger percentage
had HCG promoters (Figure 2A and B; P=2e-11,
binomial test). Similarly, ChIP-seq of H3K4me3 and
H3K27me3 marks in the HaCaT cells (see ‘Materials
Methods’ section; Supplementary Dataset S2 and S3)
showed that the cell cycle genes described here were
enriched for H3K4me3 (Figure 2C). Moreover, the genes
were also enriched for H3K4me3 marks that were present
in and common for all of seven other cell lines (13,14)
(Figure 2D), which is consistent with these genes having
housekeeping functions common to many cell types.
The cell cycle genes that showed inconsistent or no
histone modiﬁcations within their promoters were highly
enriched among LCG genes (Figure 2E and F). Tissue-
speciﬁc genes are commonly enriched among LCGs,
which suggested that this subset of cell cycle expressed
genes that have LCG promoters with no or inconsistent
H3K4me3 modiﬁcations might be cell type-speciﬁc for
HaCaT. To test this possibility, we ﬁrst investigated
whether all the human LCG genes without consistent
H3K4me3 within the seven cell lines (LCG/
NoH3K4me3) were enriched within GO categories or
KEGG pathways (18). As expected, the set of all LCG/
NoH3K4me3 genes was highly enriched for tissue speciﬁc
functions, whereas the set of all HCG/H3K4me3 genes
was enriched for housekeeping categories and pathways
(Supplementary Figure S5, Supplementary Dataset S4).
Second, by accounting for such background enrichment
within the nine subgroups, we found both the HCG/
H3K4me3 cell cycle genes and the intermediate CpG
(ICG)/H3K4me3 cell cycle genes to be speciﬁcally
enriched for cell cycle-related terms (Figure 2G).
Moreover, the LCG/NoH3K4me3 cell cycle genes were
A
B
C D
E F
G
Figure 1. PLS regression identiﬁes cyclic gene expression patterns. The
loadings (A) and scores (B) plots show the contribution of each gene
(loadings) to the location of each sample in the subspace of the PLS
model (20) (scores; here, sine and cosine, period of 20h). (A) Points show
signiﬁcant genes [q< 0.05; permutation test (21)] and their contribution
to the PLS cell cycle model’s ﬁrst and second components (PC1 and
PC2). Colours show the cell cycle phase where the gene is predominantly
expressed (see ‘Materials and Methods’ section). The circle and cell
diagrams indicate early and late DNA replication, G2, mitosis and G1
as determined by the scores plot (B) and ﬂow cytometry (Supplementary
Figure 1). (B) Points show the location of the samples from the three
replicates (point, circle and cross) within the PLS model’s ﬁrst and
second components; the line shows the replicates’ average trajectory;
numbers show the sample time (h). (C–F) Expression proﬁles for
selected genes from the loadings plot [labelled triangles in (A)]. (C)
Cyclin E2 (CCNE2); (D) Cyclin-dependent kinase inhibitor 2C
(CDKN2C); (E) Cyclin A2 (CCNA2); and (F) Cyclin-dependent kinase
inhibitor 3 (CDKN3). (G) Heatmap showing the expression changes of
the cell cycle genes relative to their median expression. The proﬁles are
ordered according the genes’ phase angle in the PLS model in (A).
Margin colours show the genes’ assigned cell cycle phase.
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speciﬁcally enriched for the KEGG cytokine–cytokine
receptor interaction pathway, which is consistent with
cytokines being important regulators of wound healing
in general and keratinocyte proliferation in particular
(25). Thus, at least some of the cell cycle genes seem to
be cell type-speciﬁc for HaCaT cells.
Distinct cell types have exclusive cell cycle regulated genes
related to the cells’ speciﬁc characteristics and functions
To further determine whether cell type-speciﬁc factors
could explain differences in reported cycling genes, we
analysed the overlap among the cell cycle-regulated
genes identiﬁed in our and previous human studies
(Figure 3). Although our study identiﬁed more cell cycle
genes than did the foreskin ﬁbroblast (FF) (3) and HeLa
(2) studies (Figure 3A), the cell cycle genes we identiﬁed
had clear cycling patterns in HaCaT. In contrast, the
genes identiﬁed in the two previous studies but missed in
our study had weak or inconsistent patterns in HaCaT;
compare Figure 3B and 3C.
Some of the differences between the studies were likely
related to differences in microarray technologies and study
A B C
E
F
D
G
Figure 2. HaCaT cell cycle genes include both generally active housekeeping and keratinocyte-speciﬁc genes. (A) Distributions of CpG content in
promoters for all genes included in the PLS model (all, dashed line) and cell cycle expressed genes (CC, solid line). The lines are the kernel density
estimates of the two CpG content distributions. (B) Fraction of LCG (black), ICG (grey) and HCG (white) promoters for the two groups in (A).
Numbers above bars are the total number of non-redundant promoter regions. (C and D) Fraction of promoters that in HaCaT (C) or in seven
different cell lines (D) contain exclusive H3K4me3 or H3K27me3 marks (K4, white; K27, dark grey), bivalent K4 and K27 marks (K4/K27, light
grey), or no or inconsistent marks (None, diamonds). P-values are the results of binomial tests comparing the fraction of H3K4me3-marked genes in
the two sets. (E and F) Fractions from (C: E) and (D: F) subdivided into LCG, ICG and HCG (black, dark grey and light grey lines) promoters.
(G) GO biological process (BP) terms or KEGG pathways signiﬁcantly enriched (P< 0.05) among HCG, ICG or LCG cell cycle genes subdivided
into promoters with consistent H3K4me3 (white) or H3K27me3 (no signiﬁcant terms) marks, or no or inconsistent marks (diamonds). Horizontal
axes show Benjamini–Hochberg corrected P-values (–log10); numbers on the right show the expected (E) and observed (O) number of genes and the
corresponding odds ratios (OR).
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designs. Microarray results are generally reproducible
across platforms and laboratories for genes with medium
and high expression (26), and the genes common for the
three studies were generally highly expressed in HaCaT
(Figure 3D). These genes were also strongly enriched for
cell cycle functions (Supplementary Table S2), indicating
that these common genes represent a core set of cell cycle
genes. As for design, although previous studies have either
not included or used poorly matched biological replicates,
we included three direct biological replicates. This,
combined with the reproducibly high level of synchroniza-
tion for the HaCaT cells, gave our study better statistical
power to identify cyclically expressed genes.
Although the cell cycle genes common for all three
studies represented a core set of human cell cycle genes,
the other subsets of cell cycle genes were at least partially
related to cell type-speciﬁc functions and characteristics
(Figure 3E). To illustrate, the GO term ‘vitamin D
receptor binding’ was overrepresented among the cell
cycle genes exclusive for HaCaT, which is consistent
with vitamin D and the vitamin D receptor’s important
functions in keratinocytes (27). In contrast, and consistent
with HeLa’s cancer origin, ‘chronic myeloid leukaemia’
was the only term exclusive for the HeLa cell cycle
genes. Further supporting this conclusion, the KEGG
pathways ‘nucleotide excision repair’ and ‘base excision
repair’ were exclusively overrepresented among the cell
cycle genes common for FF and HaCaT, which suggests
that these two DNA repair pathways are partially
dysregulated in HeLa. Although we cannot exclude that
technical differences underlie some of the differences in
gene expression (see ‘Discussion’ section), distinct cell
types do seem to have distinct cell cycle regulated genes.
For some cells, such as HeLa and likely other cancers (3),
these distinct cell cycle genes may reﬂect that the cells are
in an abnormal dysregulated state. Nevertheless, for more
A B D
C
E
Figure 3. Cell cycle genes that are common or exclusive for foreskin ﬁbroblasts (FF) (3), HeLa (2) and HaCaT reveal characteristics that are speciﬁc
for the three cell types. (A) Venn diagram showing the overlap in cell cycle genes between FF (BJ), HeLa (W) and HaCaT (33 h). (B) Heatmap
showing the expression changes of the HaCaT cell cycle genes relative to their median expression. The genes are grouped according to their overlap
with the cell cycle genes from the FF and HeLa studies and are ordered according the genes’ phase angle (from p to p) in the HaCaT 33 h PLS
model. Margin colours show the genes’ assigned cell cycle phase (red, G1/S; turquoise, S; green, G2; blue, G2/M; and pink, M/G1). (C) Heatmap
showing the expression changes in HaCaT for genes identiﬁed as cell cycle regulated in FF or HeLa but not in HaCaT. The genes are grouped
according to their overlap between the two studies and are ordered according to the genes’ phase angle in the HaCaT 33 h PLS model. (D) Median
expression level in HaCaT of the genes common and exclusive for the three studies. The genes are grouped according to their overlap between the
three studies. Boxes, horizontal black line, and circles show the ﬁrst and third quartiles, the median and outliers; whiskers show the most extreme
data points up to 1.5 times the interquartile range from the box. (E) KEGG pathways and GO molecular function (MF), biological process (BP) and
cellular component (CC) terms that are overrepresented (P< 0.05) and unique for six of the seven subsets of cell cycle genes common or exclusive for
FF, HeLa and HaCaT; see Supplementary Table S2 for pathways and terms overrepresented among cell cycle genes common for FF, HeLa and
HaCaT.
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normal non-tumorigenic cells, such as HaCaT, at least
some of the distinct cell cycle genes are related to the
cells’ speciﬁc functions.
Cell cycle genes marked with H3K27me3 are transcribed
during DNA replication
Although the cell cycle genes were generally enriched for
H3K4me3, a fraction of the cell cycle genes were marked
with H3K27me3 (Figure 2B)—the mark for genes silenced
by Polycomb group proteins (28,29). Replication opens
compacted chromatin, and although H3K27me3 marks
are copied to daughter chromatin, the marks may initially
be diluted, such that the normally silenced DNA is tran-
siently accessible for transcription during this replication
process. If this model was correct, we would expect that
cell cycle genes marked with H3K27me3 were enriched
among genes upregulated during DNA replication.
Indeed, the H3K27me3 marks in the HaCaT cells were
differentially distributed among the cell cycle genes
(Figure 4A). Of genes predominantly expressed in the
G1/S and S phases, 37% had H3K4me3 marks and 12%
had H3K27me3 marks. In contrast, of genes expressed in
G2, G2/M and M/G1, 80% contained H3K4me3, whereas
only 1% contained H3K27me3 marks. In total, 87% of
the H3K27me3 marked cell cycle genes were expressed in
G1/S or S (P=5e-17; one-tailed binomial test). Similarly,
a larger percentage of the G1/S and S phase genes was
LCG (Figure 4B). The enrichment of H3K27me3 was
not related to CpG content, as the G1/S and S phase
genes showed similar enrichment for H3K27me3 inde-
pendent of CpG content (Figure 4C). These patterns
were also consistent within the previously published data
from seven different cell lines (13,14) (Supplementary
Figure S6).
Genes upregulated in early S-phase tend to be replicated
earlier than late S-phase genes
Replication occurs in distinct domains largely
characterized by differences in GC content, and although
these domains are partly reorganized during development,
domains with high and low GC content are generally
replicated early and late in S phase, respectively (30–35).
If DNA replication facilitated transient transcription of
silenced genes, we would, therefore, expect the genes
upregulated during G1/S to generally have a higher GC
content than the S phase and other cell cycle genes.
Indeed, the G1/S genes had the highest overall GC
content of the cell cycle genes (Figure 4D; P-value of
7e-3, two-sided un-paired Student’s t-test with unequal
variance of difference in mean between G1/S and S
phase genes) and replication-timing data from three dif-
ferent cell lines (30,33) indicated that the G1/S genes on
average tended to be replicated earlier than the S phase
genes (Figure 4E, Student’s t-test P-value of 1e-3;
Supplementary Figure S7). Importantly, 63% of the cell
cycle regulated genes reside in genomic regions previously
shown to have stable replication timing across multiple
cell types (31), and these genes had the same pattern in
replication timing as the complete set of cell cycle genes
(Supplementary Figure S8).
Consistent with some of the genes residing in silenced
chromatin and being transiently expressed during repli-
cation, the G1/S and S genes had a general lower expres-
sion level than the genes expressed in the other phases
(Figure 4F). Moreover, the genes marked with
H3K27me3 in HaCaT had the lowest expression level of
the G1/S and S phase genes (Figure 4G). The differences in
expression between H3K27me3-marked genes and other
subgroups were signiﬁcant for all G1/S phase groups
(P-values of 2e-16, 2e-9, 3e-5 and 0.01 for K4, HCG,
ICG and LCG groups, respectively; two-sided un-paired
Student’s t-test with unequal variance) and for the K4 and
HCG S phase groups (P-values of 7e-4, 0.02, respectively;
P-values of 0.1 and 0.3 for ICG and LCG groups,
respectively).
Foreskin ﬁbroblasts show similar replication-related
expression of H3K27me3 marked genes
To investigate whether this replication-related cell cycle
expression pattern could be found in other cell types, we
ﬁrst used our computational framework to reanalyse the
previously published primary foreskin ﬁbroblast data (3)
(Supplementary Figure S9). As in the HaCaT cells, the
majority (64%) of the genes that had signiﬁcant cell
cycle expression and were marked with H3K27me3 in
ﬁbroblasts were upregulated during DNA replication
(Figure 5A); the mark was especially enriched for the
G1/S genes (P=0.009; one-tailed binomial test for enrich-
ment). In contrast to HaCaT, the majority of the ﬁbro-
blast cell cycle genes marked with H3K27me3 was also
marked with H3K4me3. The ﬁbroblast cell cycle genes
also showed a similar trend in GC content as the
HaCaT genes, although the difference between the genes
expressed early (G1/S) and late (S) during DNA repli-
cation was not signiﬁcant (Figure 5B; P=0.1, Student’s
t-test).
Second, we measured the gene expression proﬁles in
HeLa cells synchronized in the G2/M transition by
nocodazole and mitotic shake-off and used PLS to
identify genes with cell cycle-dependent expression
(Supplementary Figures S10 and S11). Again, the
majority (52%) of the cell cycle genes that were marked
with H3K27me3 in HeLa was upregulated during DNA
replication, but the differences between the phases were
not signiﬁcant (Figure 5C; P=0.2). Moreover, the cell
cycle genes again showed a similar trend in GC content
as the HaCaT, such that the G1/S genes had a higher GC
content than the S genes (Figure 5D; P=0.01, Student’s
t-test). Thus, replication-related expression of H3K27me3-
marked genes does not seem to be a strong characteristic
of all cell types. It is relevant to note, however, that the
characteristic is absent in the most abnormal of the three
cells, whereas HaCaT and the primary ﬁbroblasts both
have signiﬁcant replication-related expression of
H3K27me3-marked genes.
DISCUSSION
Previous studies of the gene expression patterns during the
human cell division cycle have indicated marked
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differences between primary and cancer cells (3), but our
results show that distinct cell types have distinct cell cycle
expressed genes that are related to the cells’ functions.
Speciﬁcally, by proﬁling the gene expression in synch-
ronized human HaCaT keratinocytes, we have identiﬁed
a set of cell cycle expressed genes containing known marks
for cell type-speciﬁc expression, such as low CpG content
in their promoters and few or inconsistent promoter
histone marks. These genes were enriched for functions
important for keratinocyte proliferation, such as cyto-
kine–cytokine receptor interaction.
Cell cycle regulation is an important housekeeping
function and accordingly, most of the cell cycle expressed
genes identiﬁed in our study have high CpG promoters
and the active chromatin mark H3K4me3 in multiple
cell lines. Nevertheless, we have also shown that some
genes with low CpG promoters or the silent chromatin
mark H3K27me3 have cell cycle dependent expression.
These genes are mostly expressed during S phase in a
replication-related pattern, which suggests that DNA rep-
lication can open some epigenetically silenced loci for
transcription.
Replication-dependent transcription is a mechanism
that can achieve precise transcriptional regulation during
the cell cycle, as normally silenced genes will only be
transcribed when their loci are replicated in S-phase.
Compared with the other cell cycle genes, the Polycomb-
regulated cell cycle genes in HaCaT were signiﬁcantly
enriched for the GO terms ‘GO:0007267 cell–cell
signalling’ and ‘GO:0046903 secretion’ (Benjamini–
Hochberg-corrected P-values of 0.007 and 0.02, respect-
ively). In HaCaT cells, replication-dependent transcription
may, therefore, be a regulatory mechanism for
coordinating cell–cell signalling with the cell cycle.
Lanzuolo et al. (36) have earlier reported that two
Polycomb-repressed homeotic genes show replication-
dependent expression in Drosophila S2 cells. Our results
extend this observation to humans and show that many
other genes with Polycomb-repressive marks have
replication-dependent expression. We also note that
cis-encoded RNAs do play a role in Polycomb-mediated
targeting and regulation (37–39). Given that Polycomb
regulates all transcripts in targeted loci, replication-
dependent expression may be a mechanism for expressing
such cis-encoded Polycomb-associated RNAs at existing
Polycomb-regulated loci.
When comparing our list of HaCaT cell cycle genes with
the cell cycle genes from the previous HeLa (2) and
primary foreskin ﬁbroblast studies (3), we found several
differences, such that only 125 genes were common for all
three studies (Figure 3A). Several technical factors, such
as differences in microarray technology, analytical
A B C
D E F G
Figure 4. G1/S and S phase genes are enriched for H3K27me3 marks and show replication-related expression. (A) Distribution of HaCaT H3K4me3
and H3K27me3 marks in promoters of genes upregulated in G1/S, S, G2, G2/M and M/G1 phases; see Figure 2. (B) Fractions of LCG, ICG and
HCG promoters for genes upregulated in the ﬁve cell cycle phases. (C) Distribution of histone marks from (A) subdivided by promoter CpG content.
(D–F) GC% (D), replication timing (E) and expression level (F) of genes expressed in the ﬁve cell cycle phases. GC% is the GC% in the region
deﬁned by the gene’s annotated transcription start and end sites; replication timing is the median S/G1 ratio within embryonic stem cells (33) of
regions overlapping each gene, such that values close to 100 and 0 represent early and late replication, respectively; expression is the gene’s average
microarray expression. Boxes, horizontal black line, and circles show the ﬁrst and third quartiles, the median and outliers; whiskers show the most
extreme data points up to 1.5 times the interquartile range from the box. (G) Expression levels of speciﬁc subgroups of G1/S and S phase genes.
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approach and experimental design, likely contributed to
these differences, for example, the genes that were
common for all three studies were highly expressed,
whereas the genes that were exclusive for our study were
lowly expressed in HaCaT. We could detect these HaCaT-
speciﬁc genes because our three matched biological repli-
cates gave increased statistical power to identify weak, but
consistent, cyclic expression patterns.
In addition to these technical differences, our results
also show that underlying biological differences between
the cells can explain some of the differences in cell cycle
expressed genes. Speciﬁcally, our results show that in
addition to the core genes that have cell cycle-dependent
expression in multiple cell types, some genes related to the
cell type’s speciﬁc functions and characteristics also have
cyclic expression. This is in contrast to a previous report,
which indicated that such cell-type speciﬁc expression
mostly reﬂects differences between primary and cancer
cells (3). These cancer-related differences are evident in
our analyses as well, but we also ﬁnd that genes and
pathways important to keratinocyte function, such as
cytokine–cytokine receptor interaction (25) and vitamin
D receptor binding, (27) have cell cycle-dependent expres-
sion. Both functions are important for normal
keratinocyte proliferation, which makes it unlikely that
these results are an artifact of HaCaT’s transformed
state or technical differences between the studies.
Instead, the cell cycle-dependent expression of these
genes likely reﬂects that processing of proliferative
signals from the extracellular environment should be
coordinated with the cell cycle.
We should note that as we have measured expression
changes in total cellular RNA, some of the expression
changes we have detected could potentially be explained
by cell cycle-dependent changes in RNA processing or
RNA stability instead of RNA transcription. Moreover,
our approach of chemically synchronizing cells can likely
explain some of the changes in gene expression in our
data, as the synchronization procedure likely triggers
stress-related responses that could both give false-
positive cyclic proﬁles and mask the cell-cycle-dependent
expression of some true cell cycle genes. This masking
effect could potentially explain why we did not detect
the known cell-cycle genes CDKN1A and VEGFC to
have cell cycle-dependent expression in HaCaT
(Supplementary Figure S2C and D). Our analyses,
including the good overlap between the genes we identiﬁed
and known cell-cycle-expressed genes, strong enrichment
for cell-cycle-related functions and overlap with previous
studies, do suggest, however, that the majority of the
genes we identiﬁed are true cell cycle genes.
In summary, by combining robust statistics with the
power of matched biological replicates, we have identiﬁed
a set of genes that show consistent cell cycle-dependent
expression in HaCaT cells. These genes include both
general cell cycle genes and genes speciﬁc for HaCaT
function. Some of the cell cycle genes also have
H3K27me3 marks—a histone modiﬁcation commonly
associated with Polycomb-silenced genes. We show that
in both HaCaT and primary foreskin ﬁbroblasts, these
genes are upregulated during DNA replication, which is
consistent with a mechanism where DNA replication can
open some Polycomb-repressed loci for transcription.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online:
Supplementary Tables 1 and 2, Supplementary Figures
1–11, Supplementary Methods, Supplementary Datasets
1–4 and Supplementary References [2,3,18,30,31,33,40].
ACKNOWLEDGEMENTS
The authors thank N.B. Liabakk for technical assistance
and A.D. Riggs and O. Snøve Jr for critical reading. The
sequencing service was provided by the Norwegian
Sequencing Centre (www.sequencing.uio.no), a national
technology platform hosted by the University of Oslo
and supported by the ‘Functional Genomics’ and
‘Infrastructure’ programs of the Norwegian Research
Council and the Southeastern Regional Health
Authorities of Norway.
A B
C D
Figure 5. H3K27me3 marks are enriched in genes upregulated during
DNA replication in primary foreskin ﬁbroblasts. (A) Distribution of
H3K4me3 and H3K27me3 marks in promoters of genes upregulated
in G1/S, S, G2 and M/G1 phases in primary foreskin ﬁbroblasts
synchronized by serum starvation [expression data from (3); ChIP-seq
data from normal adult dermal ﬁbroblasts (13,14)]. (B) GC% of the
genes from (A). (C) Distribution of H3K4me3 and H3K27me3 marks
in promoters of genes upregulated in G1/S, S, G2, G2/M and M/G1
phases in HeLa cells synchronized by nocodazole and mitotic shake-off
[ChIP-seq data from HeLa (13,14)]. (D) GC% of the genes from (C).
See Figures 2 and 4 for details on graphs.
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Supporting Online Material 
Supplementary Methods 1 – ChIP-seq 
Plates (75cm2) with ~6 million HaCaT cells were washed twice with PBS, then cross-
linked with 0.5% formaldehyde at room temperature for 10 mins, following which cross-
linking was quenched by the addition of glycine to 125 mM. Cells were again washed 
with PBS, then scraped from plates in PBS supplemented with 1mM EDTA and protease 
inhibitors. Cross-linked cells were collected by centrifugation at 1500 G, and 
resuspended in cold RIPA buffer (10 mM Tris pH 8.0, 1 mM EDTA, 140 mM NaCl, 1 % 
Triton X-100, 0.1% SDS, 0.1 % Na-Deoxycholate) supplemented with protease inhibitors 
at a density of 1 x 107 cells/ml. Lysed cells were then sonicated in TPX tubes 
(Diagenode) using a Bioruptor (Diagenode) for 12 mins on full power, then debris was 
removed by centrifugation in a chilled mircofuge at 16000 G for 15 mins. Soluble 
chromatin supernatant equivalent to 3.8 x 106 cells / IP was pre-cleared using 25 l of a 
1:1 mix of protein A and protein G Dynabeads (Invitrogen), then used for overnight 
immunoprecipitation using either 4 g anti-H3K4me3 antisera (Diagenode s.a., Cat. # 
pAb-003-050; Lot # A2-002P) or 2 g anti H3K27me3 (Upstate Biotechnology, Cat. # 
07-449; Lot # DAM1387952). Antibody-protein complexes were immunoprecipitated 
with protein A/G Dynabeads, then washed 5 times with RIPA buffer supplemented with 
protease inhibitors, once with LiCl wash buffer (250 mM LiCl, 10 mM Tris pH 8.0, 1 
mM EDTA, 0.5 % Igepal CA-630, 0.5 % Na-deoxycholate) supplemented with protease 
inhibitors, and once in TE. Immunoprecipitated DNA was isolated by successive RNaseA 
and proteinase K treatment, followed by purification over Genomic DNA cleanup & 
concentrator columns (Zymo Research Corp.). Two ng of immunoprecipitated material, 
or input chromatin isolated as above, was used for library preparation using TruSeq™ 
DNA Sample Preparation reagents (Illumina), and submitted to the Norwegian 
Sequencing Centre for sequencing on a HiSeq 2000 (Illumina). IP and control input 
libraries were clustered on a single lane of an Illumina flowcell using TruSeq™ SR 
Cluster Kit v3 reagents and subjected to 50 bases of sequencing using TruSeq™ SBS v3 
reagents (Illumina). Image analysis and base calling was performed using Illumina's RTA 
software version 1.12.4.2. Demultiplexing and conversion from bcl file to fastq file was 
performed using CASAVA v1.8.2. Reads were filtered to remove those with low base 
call quality using Illumina's default chastity criteria. 
Supplementary Discussion 1 – A PLS model based only on the first 
24 hours after release identifies additional cell cycle regulated genes 
at the expense of additional false positives 
When studying the list of genes with previously published phases and the genes on that 
list not detected by our PLS model to be cell cycle expressed in HaCaT, we noticed that 7 
of the 12 missing genes were previously published to be expressed in S phase 
(Supplementary Table 1). Closer inspection of the expression profiles indicated that some 
of these genes appeared to have a cyclic expression pattern during the first cell division. 
We therefore created a new PLS model based on only the first 24 hours after release 
(Supplementary Fig. 3). This model identified several additional cell cycle genes, 
including 4 of the 12 genes missed by the PLS model based on all the 33 hours after 
release (Supplementary Fig. 4, Supplementary Table 1). Although the 24 hours PLS 
model gave an increased coverage of known cell cycle genes of about 8%, this was at the 
expense of about 9% additional significant cell cycle genes than the 33 hours model. 
Using all the available probes on the chip instead of only the probe that showed the 
highest variation for each Entrez gene further increased the coverage of known cell cycle 
genes to 42 of 48 genes, but also increased the total number of significant cell cycle 
genes to 2081 (data not shown). To limit the influence of potential false positives and 
focus our analyses on genes that showed consistent cyclic expression across multiple cell 
divisions, we therefore decided to use the 33 hours PLS model as basis for further 
analyses. 
Supplementary Figure 1 - Synchrony of double thymidine blocked HaCaT cells. () 
Cell synchrony was monitored by flow cytometry of propidium iodide-stained cells. The 
figures show for each time point, superimposed profiles of three replicate synchronization 
experiments. Horizontal axes show DNA content (arbitrary units) and vertical axes show 
the number of events (cells) with the corresponding DNA content. () Percentage of cells 
assigned to G1, S, and G2/M phases for each of the time points analyzed. Values and 
error bars are averages and standard deviations (n = 3). 
Supplementary Figure 2 - “Missing” cell cycle genes either show no cyclic 
expression or have more variance between replicates than “detected” cell cycle 
genes. () The figure shows the average expression variance across the 12 time points 
(var(replicates); variance averaged over the 3 replicates) minus the average expression 
variance across the 3 replicates (var(timepoints); variance averaged over the 12 time 
points) for the previously known cell cycle regulated genes (table S2) detected (“Sig.”) 
and not detected (“Not sig.”) to be significantly cell cycle regulated in HaCaT by this 
study. All the significant genes have higher average variance within a replicate than 
within time points. In contrast, 6 of the 12 “missing” genes (BRCA1, BRCA2, DHFR, 
MSH2, RRM1, and RAD21) have lower average variance within a replicate than within 
time points; that is, their expression was inconsistent and varied as much between the 
replicates as within the same replicate. Only three of the “missing” genes (CDKN1A, 
NASP, and VEGFC) had a difference in average variance that was greater than any of the 
significant genes. Arrows and labels show these three “missing” genes with the largest 
difference in average variance () and the two significant genes with the smallest 
difference in average variance (). () Expression patterns for the five genes 
annotated in (). The “missing” genes () do not show cyclic expression patterns 
through both cell cycles, whereas the significant genes do (). () NASP showed an 
expression pattern consistent with being up-regulated during S phase and down-regulated 
during G2/M phase in the first cell cycle but not in the second; that is, NASP was down-
regulated in the first G2/M phase (9 and 12 hours after release), but not in the second 
G2/M phase (27 and 30 hours after release). () CDKN1A and VEGFC were highly 
expressed in the first G1/S transition and S phase, but were not up-regulated in the second 
cell cycle. Figure titles show the probe id, the false discovery rate (q), and the gene name. 
Supplementary Figure 3 – A cyclic PLS model based on the first 24 hours after 
release identifies additional genes expressed in S phase in HaCaT. () Known cell 
cycle genes cluster according to their published cell cycle phase. (Left) Loadings plot 
showing significant genes (q < 0.05; permutation test) and the genes with known cell 
cycle expression (Supplementary Table 2) in the cyclic PLS models based on all the 33 
hours () and only the first 24 hours () after release from double thymidine block. The 
genes with known cell cycle expression are color-coded according to their known cell 
cycle phase (red, G1/S; turquoise, S; green, G2; blue, G2/M; and pink, M/G1). (Right) 
Phase angle probability distributions for the five cell cycle phases estimated based on the 
phase angles of the known cell cycle genes in the loadings plot (see Methods). Horizontal 
axis shows the phase angle (radians); vertical axis shows the probability. Note that 
because the horizontal axis represents a linearization of a circle, the distributions “wrap 
around” from  to -. () The 24 hours PLS model identifies more genes as significant 
cell cycle genes than the 33 hours PLS model and the largest increase is for genes 
expressed in S phase. The bar graphs show the relative distribution of significant genes (q 
< 0.05) in the five cell cycle phases for the 33 hours and 24 hours PLS models. The 
numbers above the bars show the total number of significant genes in each model. Note 
that the 24 hours model gave poorer separation of the G2/M and M/G1 phases than the 33 
hours model (compare phase angle probability distributions in () and ()), which 
resulted in the 24 hours model having fewer genes in G2/M phase than the 33 hours 
model had. () Loadings () and scores () plots for the cyclic PLS model based on 
only the first 24 hours after release from double thymidine block. The solid, dashed, and 
dotted lines in () show the trajectories for the three biological replicates. Labeled 
triangles in () show the location of the four selected genes in Fig. 1: () CCNE2; () 
CDKN2C; () CCNA2; and () CDKN3. See Figure 1 for the four genes’ expression 
profiles and additional details regarding loadings and scores plots. 
Supplementary Figure 4 – Expression patterns of the four known cell cycle 
regulated genes identified by the 24 hours PLS model () but missed by the 33 hours 
PLS model (). Figure titles show the probe id, the false discovery rate (q), and the gene 
name. Except for RAD21, the additional genes detected by the 24 hours model were 
predominantly expressed in G1/S or S phase. 

Supplementary Figure 5 – High-CpG and consistent H3K4me3 are associated with 
housekeeping functions whereas low-CpG and no or inconsistent H3K4me3 are 
associated with cell type-specific functions. The barplots show the five most 
significantly KEGG pathways (KEGG), or GO molecular function (MF) or biological 
process (BP) terms overrepresented among all genes with high, intermediate, or low CpG 
promoters and consistent H3K4me3, H3K27me3, or lack of consistent H3K4me3 
modifications. Horizontal axes show Benjamini-Hochberg corrected p-values (–log10); 
numbers on the right show the expected (E) and observed (O) number of genes and the 
corresponding odds ratios (OR). Cell type-specific functions such as “Olfactory 
transduction” are strongly overrepresented among LCG/NoH3K4me3 genes whereas 
housekeeping functions such as “cellular metabolic process” are overrepresented among 
HCG/H3K4me3 genes. 
Supplementary Figure 6 - G1/S and S phase genes are consistently enriched for 
H3K27me3 marks within multiple cell lines. (A) Distribution of consistent H3K4me3 and 
H3K27me3 marks in promoters of genes upregulated in G1/S, S, G2, G2/M, and M/G1 phases; 
see Fig. 4. (B) Fractions of low-CpG (LCG), intermediate-CpG (ICG), and high-CpG (HCG) 
promoters for genes upregulated in the five cell cycle phases. (C) Promoter chromatin states for 
cell cycle genes within the NHEK keratinocyte cell line show that poised and Polycomb-
regulated promoters are strongly enriched whereas promoters with heterochromatin regions are 
weakly enriched among genes expressed during DNA replication. The bar graphs show the 
fraction of promoters that contain regions classified by a published “Chromatin-state” Hidden 
Markov Model (1) to be Active, Weak, and Poised promoters and Polycomb-repressed and 
Heterochromatic regions. Lines and numbers within the graphs indicate chromatin states (Poised, 
Polycomb, and Heterochrom) that are enriched among genes expressed during DNA replication 
(G1/S and S phases; numbers are p-values from one-tailed binomial tests). 
Supplementary Figure 7 – Data from different cell lines show that HaCaT G1/S 
genes tend to be replicated earlier than S genes. The box plots show the replication 
timing of cell cycle genes from HaCaT in () basophilic erythroblasts (2) and () 
lymphoblastoid cells (3). The replication timing is the median S/G1 ratio of regions 
overlapping each gene; data from sequencing-based TimEX () are normalized S/G1 
ratios (see (2)); data from microarray-based hybridization experiments () are probe 
S/G1 ratios (see (3)). For () early and late replicating regions have values close 100 and 
0, respectively, whereas for () early and late replicating regions have values close to 2 
and 1, respectively. Boxes, horizontal black line, and circles show the first and third 
quartiles, the median, and outliers; whiskers show the most extreme datapoints up to 1.5 
times the interquartile range from the box.  
Supplementary Figure 8 – Replication timing for genes residing in regions with 
stable replication timing. (A) Replication timing within all cell cycle genes that do not 
overlap regions found by Hansen and colleagues to exhibit replication timing plasticity 
(4). The data is a subset of Figure 4E where all transcripts that overlap regions with 
replication timing plasticity have been removed (regions of replication timing plasticity 
were defined in Supplementary Table S2 in (4)) (B) Replication timing within the subset 
of genes from (A) that are marked with H3K27me3 within their promoters. (A-B) 
Replication timing is the median S/G1 ratio within embryonic stem cells (2) of regions 
overlapping each gene. See Supplementary Figure 7 for details on the box-and-whisker 
plots. 
Supplementary Figure 9 – Partial least squares (PLS) regression reanalysis of serum 
starved primary foreskin fibroblasts identifies cell cycle genes.() Loadings () 
and scores () plots for a cyclic PLS model of the gene expression profiles from Bar-
Joseph and colleagues’ primary foreskin fibroblast experiment (5). The period used was 
30 hours estimated based on the cells’ DNA content profile (Fig. 1a in (5)). Labeled 
triangles in () show the location of the four selected genes from Figure 1 and panels (
) show their expression profiles. The genes are () CCNE2; () CDKN2C; () CCNA2; 
and () CDKN3. See Figure 1 for additional details regarding loadings and scores plots. 
() Loadings plot showing the genes with known cell cycle expression (Supplementary 
Table 2) in the PLS model (). (	) Phase angle probability distributions for four of the 
five cell cycle phases. Specifically, we excluded the G2/M phase from the model, as the 
experiment, in contrast to the HaCaT double thymidine block experiment (Fig. 1; 
Supplementary Figure 3a), did not give sufficient temporal resolution to accurately 
separate the genes in the G2/M phase from the G2 and M/G1 phases; compare the 
patterns for the genes with known cell cycle expression in Supplementary Figure 3a with 
their pattern in (). In Supplementary Figure 3a, these known genes are well separated, 
whereas in the primary foreskin fibroblast data, the genes are clustered at the end of the 
series and the G2/M phase genes completely overlap the G2 and M/G1 genes. Also 
shown in (	) is the phase angle probability distribution for the G1 phase, as estimated by 
the cells’ DNA content profile. These phase angles had a marked lack of known cell 
cycle genes (see ), and were therefore excluded from the model. The final cell cycle 
model, which included the G1/S, S, G2, and M/G1 phases, consisted of 627 distinct genes 
and included 60% of the genes originally reported by Bar-Joseph and colleagues. See 
Methods and Supplementary Figure 3 for additional details. 
Supplementary Figure 10 – Synchrony by nocodazole and mitotic shake-off blocked 
HeLa cells. ( and ) Cell synchrony was monitored by flow cytometry of propidium 
iodide-stained cells. The figures show for each of the two biological replicates, DNA 
profiles at each time point of the synchronization experiment. Horizontal axes show DNA 
content (arbitrary units) and vertical axes show the number of events (cells) with the 
corresponding DNA content. () Percentage of cells assigned to G1, S, and G2/M phases 
for each of the time points analyzed. Values and error bars are averages and standard 
deviations (n = 2). 
Supplementary Figure 11 – Nocodazole, mitotic shake-off, and partial least squares 
(PLS) regression identifies HeLa cell cycle genes.() Loadings () and scores () 
plots for a cyclic PLS model of the gene expression profiles from HeLa cells 
synchronized by nocodazole treatment and mitotic shake-off. The period used was 25 
hours estimated based on the cells’ DNA content profile (Supplementary Fig. 10). 
Labeled triangles in () show the location of the four selected genes from Figure 1 and 
panels () show their expression profiles. The genes are () CCNE2; () CDKN2C; () 
CCNA2; and () CDKN3. See Figure 1 for additional details regarding loadings and scores 
plots. () Loadings plot showing significant genes (q < 0.05; permutation test) and the 
genes with known cell cycle expression (Supplementary Table 2) in the PLS model (). 
(	) Phase angle probability distributions for the five cell cycle phases. See Methods and 
Supplementary Figure 3 for additional details. 
Supplementary Table 1 - List of genes with previously published phases. The genes 
are from Table 2 in (6). “Predicted (33 h)” are the cell cycle phases assigned by this 
study’s main PLS model for the HaCaT cells, which is based on all the time points up to 
33 h after release; “Predicted (24 h)” are the cell cycle phases assigned by a PLS model 
based on only the time points up to 24 h after release (in HaCaT); “Whitfield” are the cell 
cycle phases reported based on microarray analyses of synchronized HeLa cells (6); 
“Actual” are previously reported cell cycle phases as compiled by (6). 
Gene Predicted (33 h) Predicted (24 h) Whitfield Actual 
E2F5 G2 G2 G2/M G1 
CCNE1 G1/S G1/S G1/S G1/S 
CCNE2 G1/S G1/S G1/S G1/S 
CDC25A G1/S G1/S G1/S G1/S 
CDC45L S S S G1/S
CDC6 G1/S G1/S G1/S G1/S 
CDKN1A ND ND ND G1/S 
E2F1 G1/S G1/S G1/S G1/S 
MCM2 G1/S G1/S G1/S G1/S 
MCM6 G1/S G1/S G1/S G1/S 
NPAT ND ND G1/S G1/S 
PCNA G1/S G1/S G1/S G1/S 
SLBP G1/S G1/S G1/S G1/S 
BRCA1 ND ND S S
BRCA2 ND ND ND S 
CCNG2 S S ND S 
CDKN2C S S G2 S 
DHFR ND ND S S
MSH2 ND G1/S G1/S S 
NASP ND G1/S G1/S S 
RRM1 ND ND S S
RRM2 G1/S S S S
TYMS ND S S S
CCNA2 G2 G2 G2 G2 
CCNF G2 G2 G2 G2 
CENPF G2 G2 G2/M G2 
TOP2A G2 G2 G2 G2 
BIRC5 M/G1 ND G2/M G2/M 
BUB1 G2/M G2/M G2/M G2/M 
BUB1B G2/M G2/M G2/M G2/M 
CCNB1 G2/M G2/M G2/M G2/M 
CCNB2 M/G1 M/G1 G2/M G2/M 
CDK1 G2 G2 G2 G2/M 
CDC20 M/G1 M/G1 G2/M G2/M 
CDC25B G2/M G2/M G2/M G2/M 
CDC25C G2/M G2 G2 G2/M 
CDKN2D ND ND G2/M G2/M 
CENPA G2 G2 G2/M G2/M 
CKS1B G2/M G2/M G2 G2/M 
CKS2 G2/M G2/M G2/M G2/M 
PLK1 G2/M G2/M G2/M G2/M 
AURKA G2 G2 G2/M G2/M 
RACGAP1 G2/M G2/M NM G2/M 
KIF20A G2/M M/G1 NM G2/M 
RAD21 ND G2/M M/G1 M/G1 
PTTG1 M/G1 M/G1 M/G1 M/G1 
VEGFC ND ND ND M/G1 
CDKN3 M/G1 M/G1 M/G1 M/G1 
ND: Not determined; the gene was not detected as having a significant cell cycle 
expression pattern. NM: Not measured; the gene was not present on the microarray used 
by (6). 
Supplementary Table 2 - Cell cycle genes common for foreskin fibroblasts (FF) (5), 
HeLa (6), and HaCaT are strongly enriched for cell cycle-related terms. The table 
shows all KEGG pathways and GO molecular function (MF), biological process (BP), 
and cellular component (CC) terms that are overrepresented (p < 0.05) among the 125 
cell cycle Entrez genes common for FF, HeLa, and HaCaT. The table is sorted based on 
the Benjamini-Hochberg-corrected p-value (p) of a hypergeometric test for 
overrepresentation, which for the GO terms was conditioned on the structure of the GO 
graph (7). Exp. and Count are the expected and observed number of genes; OR is the 
corresponding odds ratio; Size is the size of the background group used in the test. Rows 
shaded in gray indicate terms that were not significant (p < 0.05) among any of the other 
subsets of cell cycle genes common or exclusive for FF, HeLa, or HaCaT (see fig. S6). 
Ontology Term ID p OR Exp. Count Size 
BP organelle fission GO:0048285 2e-45 43.1 2.0 44 250
BP cell division GO:0051301 1e-33 34.6 1.7 35 230
BP M phase GO:0000279 3e-33 30.0 2.2 37 309
BP cell cycle process GO:0022402 8e-31 27.3 2.4 36 359
KEGG Cell cycle 04110 3e-30 72.9 1.1 26 129 
BP mitotic cell cycle GO:0000278 1e-29 28.0 2.1 34 309
BP mitosis GO:0007067 1e-26 40.1 1.1 26 157
CC non-membrane-bounded organelle GO:0043228 2e-19 6.6 17.3 61 2351
CC nucleoplasm GO:0005654 1e-17 9.2 5.7 36 770
CC organelle lumen GO:0043233 2e-17 6.6 12.3 50 1670 
BP DNA replication GO:0006260 3e-16 22.8 1.2 20 158
CC intracellular organelle GO:0043229 2e-15 8.7 62.3 104 8480
BP cellular component organization GO:0016043 2e-14 6.5 13.4 48 1960 
CC intracellular GO:0005622 9e-14 18.2 76.7 111 10435
CC membrane-bounded organelle GO:0043227 2e-12 5.4 55.3 95 7530
CC organelle part GO:0044422 7e-12 7.2 9.8 36 2115 
BP chromosome organization GO:0051276 1e-11 8.9 3.7 25 460
CC condensed chromosome GO:0000793 1e-11 25.5 0.7 13 91
KEGG DNA replication 03030 3e-10 48.9 0.3 9 36 
CC spindle GO:0005819 2e-9 29.6 0.4 10 65
CC chromosome GO:0005694 1e-8 12.4 1.4 14 221
BP phosphoinositide-mediated 
signaling 
GO:0048015 2e-8 22.4 0.6 11 78 
CC condensed chromosome
kinetochore 
GO:0000777 3e-8 39.8 0.3 8 38 
BP DNA packaging GO:0006323 7e-8 16.5 0.9 12 112 
BP spindle organization GO:0007051 1e-7 138.5 0.1 6 12 
BP regulation of cyclin-dependent 
protein kinase activity 
GO:0000079 2e-7 28.1 0.4 9 52 
BP chromosome segregation GO:0007059 5e-7 24.9 0.5 9 59 
CC nucleus GO:0005634 9e-7 4.9 12.8 33 3157
CC microtubule cytoskeleton GO:0015630 1e-6 12.6 1.0 11 180 
MF protein binding GO:0005515 3e-6 3.6 44.1 71 6555
CC centrosome GO:0005813 6e-6 10.4 1.2 11 175
MF ATP binding GO:0005524 1e-5 3.7 10.8 31 1426
BP G2 phase of mitotic cell cycle GO:0000085 1e-5 513.4 0.0 4 5 
BP cell cycle GO:0007049 2e-5 16.3 0.7 9 175
MF microtubule motor activity GO:0003777 2e-5 16.6 0.6 8 76
MF adenyl nucleotide binding GO:0030554 4e-5 3.4 11.5 31 1518 
CC chromosome passenger complex GO:0032133 6e-5 Inf 0.0 3 3 
MF nucleoside binding GO:0001882 6e-5 3.3 11.7 31 1544
BP DNA repair GO:0006281 1e-4 7.9 1.8 12 230
BP cellular response to stimulus GO:0051716 2e-4 4.5 5.3 20 656 
CC midbody GO:0030496 4e-4 56.0 0.1 4 14 
BP regulation of mitosis GO:0007088 4e-4 24.2 0.3 6 40 
CC microtubule GO:0005874 4e-4 7.4 1.5 10 216 
BP cell proliferation GO:0008283 6e-4 3.8 7.3 23 914 
KEGG p53 signaling pathway 04115 8e-4 12.7 0.6 6 69 
CC cytosol GO:0005829 8e-4 3.4 7.6 22 1035 
CC chromosome, centromeric region GO:0000775 1e-3 22.2 0.3 5 41
BP positive regulation of nuclear 
division 
GO:0051785 1e-3 32.3 0.2 5 25 
CC DNA replication factor C complex GO:0005663 1e-3 138.7 0.0 3 6 
MF purine ribonucleotide binding GO:0032555 1e-3 2.9 13.4 31 1772
BP mitotic sister chromatid segregation GO:0000070 1e-3 66.6 0.1 4 12 
KEGG Mismatch repair 03430 1e-3 27.0 0.2 4 23 
BP microtubule-based movement GO:0007018 1e-3 11.0 0.8 8 104 
BP establishment of chromosome 
localization 
GO:0051303 1e-3 388.6 0.0 3 4 
BP nucleosome assembly GO:0006334 2e-3 13.4 0.6 7 77 
CC outer kinetochore of condensed 
chromosome 
GO:0000940 2e-3 104.0 0.1 3 7 
BP DNA replication initiation GO:0006270 3e-3 52.3 0.1 4 14 
BP regulation of organelle organization GO:0033043 3e-3 10.0 0.9 8 117 
CC spindle microtubule GO:0005876 3e-3 31.1 0.2 4 22 
CC nuclear chromosome GO:0000228 4e-3 8.8 0.9 7 120
BP chromatin assembly or disassembly GO:0006333 5e-3 9.2 1.0 8 124 
MF DNA-dependent ATPase activity GO:0008094 6e-3 16.3 0.4 5 47
BP mitotic cell cycle spindle assembly 
checkpoint 
GO:0007094 1e-2 95.3 0.1 3 7 
MF 5'-flap endonuclease activity GO:0017108 1e-2 Inf 0.0 2 2 
BP cytokinesis GO:0000910 2e-2 17.5 0.3 5 42 
CC nucleolus GO:0005730 2e-2 3.4 5.0 15 675
MF hydrolase activity, acting on acid 
anhydrides, in phosphorus-
containing anhydrides 
GO:0016818 2e-2 3.4 5.4 16 712 
BP negative regulation of mitosis GO:0045839 2e-2 76.3 0.1 3 8 
MF nucleotide binding GO:0000166 2e-2 2.4 16.3 32 2156
CC cytoplasm GO:0005737 2e-2 2.0 50.4 70 6857 
CC spindle pole centrosome GO:0031616 2e-2 275.0 0.0 2 3 
BP regulation of ubiquitin-protein 
ligase activity 
GO:0051438 2e-2 11.3 0.6 6 75 
BP positive regulation of cell cycle GO:0045787 2e-2 15.8 0.4 5 46 
KEGG Small cell lung cancer 05222 2e-2 8.0 0.7 5 86 
BP mitotic cell cycle checkpoint GO:0007093 3e-2 25.6 0.2 4 25 
CC kinesin complex GO:0005871 3e-2 32.0 0.1 3 16 
BP cellular biopolymer metabolic 
process 
GO:0034960 3e-2 2.2 43.9 65 5477 
BP regulation of catalytic activity GO:0050790 4e-2 3.4 5.7 17 716 
BP regulation of phosphate metabolic 
process 
GO:0019220 4e-2 4.4 3.1 12 383 
BP cellular macromolecular complex 
subunit organization 
GO:0034621 4e-2 4.3 3.1 12 385 
BP establishment or maintenance of 
microtubule cytoskeleton polarity 
GO:0030951 5e-2 Inf 0.0 2 2 
BP DNA replication-dependent 
nucleosome assembly 
GO:0006335 5e-2 Inf 0.0 2 2 
BP positive regulation of mitotic 
metaphase/anaphase transition 
GO:0045842 5e-2 Inf 0.0 2 2 
BP mitotic chromosome movement 
towards spindle pole 
GO:0007079 5e-2 Inf 0.0 2 2 
BP mitotic spindle elongation GO:0000022 5e-2 Inf 0.0 2 2 
BP DNA replication, removal of RNA 
primer 
GO:0043137 5e-2 Inf 0.0 2 2 
BP regulation of kinase activity GO:0043549 5e-2 5.1 2.2 10 272 
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